Antibody-drug conjugates
ADCs targeting intracellular c-Kit epitopes address treatment resistance in cancers with c-Kit mutations, achieving effective tumor inhibition and reduced side effects.
Patent Information
- Application Number
- CN202280094970.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-17
- Publication Date
- 2024-12-03
AI Technical Summary
Current treatments for cancers with c-Kit mutations, such as GIST, acute myeloid leukemia, terminal melanoma, and testicular cancer, are limited by resistance to small molecules like imatinib, and antibody-drug conjugates targeting extracellular domains are ineffective against intracellular mutations.
Development of antibody-drug conjugates (ADCs) that specifically target the intracellular epitopes of human c-Kit using anti-c-Kit antibodies linked to cleavable linkers and cytotoxic drugs, allowing for targeted delivery to cancer cells.
The ADCs effectively inhibit tumor growth and reduce cancer recurrence by specifically targeting c-Kit mutations, providing a therapeutic option with reduced side effects and improved efficacy compared to small molecules.
Smart Images

Figure CN119072334A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an antibody-drug conjugate targeting c-Kit and uses thereof. Background Art
[0002] When stem cell factor (SCF) binds to c-Kit (also known as CD117), it can activate multiple signal transduction pathways, including phosphoinositide 3-kinase, phospholipase C-γ, Src kinase, Janus kinase-signal transduction and transcription activator (Yasuda A et al., Dig Dis Sci 52, 2292-2300. (2007); Sun J, Pedersen M & Ronnstrand L, J Biol Chem 284, 11039-11047. (2009)).
[0003] Previous studies have reported that the expression of c-Kit with oncogenic mutations is unregulated or upregulated in various cancers, leading to SCF-independent c-Kit activation and cell proliferation. Overexpression of c-Kit is activated by various transcription factors including AP-2, ETS, SP1, MYB, and MITF and induced by hypoxia. More than 500 c-Kit mutations have been identified in human tumors (Sanger Institute Catalog of Somatic Mutations in Cancer, 2011). https: / / cancer.sanger.ac.uk ). SCF-independent spontaneously activating c-Kit mutations were detected in approximately 85%, 30%, 25%, 25% and 90% of gastrointestinal stromal tumors (GIST), acute myeloid leukemia, terminal melanoma, testicular cancer and systemic mastocytoma (SM) (Lennartsson J & Ronnstrand L, Physiol Rev 92, 1619-1649. (2012)).
[0004] The efficacy of small molecules such as imatinib for removing cancer stem cells carrying constitutively activated mutations of c-Kit is limited in tumor cells carrying mutations at different sites. In order to overcome the resistance to treatment induced by c-Kit mutations, various small molecules such as dasatinib, sunitinib, and axitinib have been developed (Abbaspour Babaei M et al., Drug Des Devel Ther 10, 2443-2459. (2016)). However, the proportion of grade 3 / 4 abnormal reactions in patients treated with these small molecules is higher than that in patients treated with imatinib, thus limiting its effective application in cancer treatment (Kantarjian HM et al., Blood 119, 1123-1129. (2012)).
[0005] Antibody-drug conjugates (ADCs) utilize the specificity of monoclonal antibodies to cancer cells to achieve the delivery of strong cytotoxic agents. In recent years, various ADCs targeting CD30 (Brentuximab Vedotin), CD22 (Inotuzumab ozogamicin), CD79b (Polatuzumab vedotin), and HER2 (Trastuzumab emtansine and Trastuzumab deruxtecan) have been approved by the U.S. Food and Drug Administration (FDA) (Leung Det al., Antibodies (Basel) 9, 2. (2020)). These ADCs are antibody-based drugs that bind to the extracellular domain of the target molecule, and therefore have no mutations that occur primarily in the intracellular domain, and can be used without regard to various mutations. Summary of the invention
[0006] Technical problem to be solved by the invention
[0007] The object of the present invention is to provide an antibody-drug conjugate of the following formula:
[0008] Ab-(L1) m -(S) n -(L2) p -(D) q
[0009] In the formula, Ab is an anti-c-Kit antibody or an antigen-binding fragment thereof that specifically binds to the epitope of human c-Kit in sequence number 9 and sequence number 10; L1 is a linker connecting the Ab and S or connecting Ab and L2; S is a spacer in the form of being connected to a polymer or not connected to a polymer; L2 is a cleavable linker; D is a drug portion; m is an integer from 0 to 8; n is an integer from 0 to 8; p is an integer from 1 to 8; and q is an integer from 1 to 8.
[0010] Another object of the present invention is to provide an antibody-drug conjugate of the following formula:
[0011] Ab-(L) x -(D) y
[0012] In the formula, Ab is an anti-c-Kit antibody or an antigen-binding fragment thereof that specifically binds to the epitope of human c-Kit in sequence number 9 and sequence number 10; L is a linker including a cleavable linker; D is a drug moiety; x is an integer from 1 to 8; and y is an integer from 1 to 8.
[0013] Another object of the present invention is to provide a composition comprising the antibody-drug conjugate.
[0014] Another object of the present invention is to provide a method for preventing or treating cancer, which method comprises the step of administering a pharmaceutically effective amount of the composition to a subject in need of the composition.
[0015] Another object of the present invention is to provide the composition for use in therapy.
[0016] Another object of the present invention is to provide a pharmaceutical composition for cancer prevention or treatment comprising the antibody-drug conjugate.
[0017] Another object of the present invention is to provide a method for preparing the pharmaceutical composition.
[0018] Another object of the present invention is to provide a composition for cancer diagnosis comprising the antibody-drug conjugate.
[0019] Another object of the present invention is to provide a method for providing information for cancer diagnosis, the method comprising: a step of treating the antibody-drug conjugate to a sample separated from a subject.
[0020] Another object of the present invention is to provide a method for producing an anti-c-Kit antibody-drug conjugate, the method comprising: m -(S) n -(L2) p -(D) q Steps for coupling to an antibody or antigen-binding fragment thereof (Ab) that specifically binds to human c-Kit:
[0021] In the formula, L1 is a linker connecting the Ab and S or connecting Ab and L2; S is a spacer in the form of being connected to a polymer or not connected to a polymer; L2 is a cleavable linker; D is a drug moiety; m is an integer from 0 to 8; n is an integer from 0 to 8; p is an integer from 1 to 8; and q is an integer from 1 to 8.
[0022] Another object of the present invention is to provide a method for producing an anti-c-Kit antibody-drug conjugate, the method comprising: a step of coupling a linker (L)-drug (D) in an antibody or an antigen-binding fragment thereof comprising a heavy chain CDR1 of sequence number 1, a heavy chain CDR2 of sequence number 2, a heavy chain CDR3 of sequence number 3, a light chain CDR1 of sequence number 4, a light chain CDR2 of sequence number 5, and a light chain CDR3 of sequence number 6, the method being characterized in that the L is a linker comprising a cleavable linker, and the D is a drug portion.
[0023] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, the scope of protection claimed for the invention and the accompanying drawings.
[0024] Means for solving technical problems
[0025] The present invention relates to antibody-drug conjugates and uses thereof, and indicates that, for example, cancer can be controlled, treated, alleviated or reduced, or cancer recurrence can be inhibited by administering an antibody-drug conjugate comprising an antibody or an antigen-binding fragment thereof that specifically binds to human c-Kit.
[0026] To facilitate understanding of the present invention, various terms and phrases are defined. Additional definitions are set forth throughout the detailed description.
[0027] I. Definitions
[0028] In this specification, the term "about" is used as approximately, roughly, around, or in the region of ~. When the term "about" is used with a numerical range, the range is modified by extending the boundaries upward and downward to the proposed numerical value. Generally, the term "about" can modify a numerical value to a value above or below the proposed value, for example, a change of 10% up or down (higher or lower).
[0029] In addition, "and / or" should be interpreted as each of the two specified features or components being specifically disclosed together with the remaining one or individually. Therefore, the term "and / or" used in statements such as "A and / or B" is intended to include "A and B", "A or B", "A" (alone), and "B" (alone). Similarly, the term "and / or" used in statements such as "A, B and / or C" is intended to include A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone) respectively.
[0030] The terms "treat", "therapeutic" and "treatment" as used in this specification refer to any intervention or process performed on a subject, or the administration of an activating agent to a subject, for the purpose of reversing, ameliorating, alleviating, hindering or delaying the progression, occurrence, severity or recurrence of symptoms, complications, conditions or biochemical indicators associated with a disease. Treatment can be performed on subjects with the disease or on subjects without the disease (e.g., prevention).
[0031] The term "administration" as used in this specification refers to the physical introduction of a therapeutic agent or a composition comprising a therapeutic agent into a subject using any of the various methods and delivery systems known to those of ordinary skill in the art to which the present invention belongs. Different routes of administration for the antibody-drug conjugates disclosed in this specification include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, for example, by injection or infusion. The term "parenteral administration" as used in this specification generally refers to other modes of administration other than enteral administration and topical administration by injection, although not limited, including intravenous, intraperitoneal, intramuscular, intraarterial, intraspinal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, intratracheal, pulmonary, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraventricular, intravitreal, epidural, and substernal injection and infusion, and in vivo electroporation. Alternatively, the antibody-drug conjugate disclosed in this specification can be administered by a parenteral route, for example, by a topical, epithelial or mucosal administration route, for example, by an intranasal, oral, vaginal, rectal, sublingual or topical route. In addition, administration can be performed, for example, once, multiple times, and / or over an extended period of more than one time.
[0032] The term "therapeutically effective amount" used in this specification refers to a drug dosage that is used alone or in combination with other therapeutic agents to effectively "treat" a disease or disorder of a subject, or effectively reduce the risk, potential, possibility or occurrence of a disease or disorder (e.g., cancer). A "therapeutically effective amount" includes the amount of a drug or therapeutic agent that provides a partial improvement or benefit to a subject suffering from a disease or disorder (e.g., cancer) or risk. Therefore, a "therapeutically effective amount" is a dose that reduces the risk, potential, possibility or occurrence of a disease or disorder, or provides partial relief, relief and / or reduction of at least one indicator (e.g., cancer) and / or reduction of at least one clinical symptom of a disease or disorder.
[0033] The term "cancer" as used in this specification refers to various diseases of a wide range of people characterized by the uncontrolled growth of abnormal cells in the body. "Cancer" or "cancer tissue" may include a tumor. Unregulated cell division and growth may lead to the formation of malignant tumors that invade neighboring tissues, which may also be transferred to distant parts of the body via the lymphatic system or blood flow. It can be said that after metastasis, distal tumors "derive from" the pre-metastatic tumor. For example, a "tumor derived from" a melanoma refers to a tumor that is a result of a melanoma that has metastasized. Since the distal tumor is derived from the pre-metastatic tumor, the tumor "derived from" may also include the pre-metastatic tumor, for example, a tumor derived from a melanoma may include a melanoma.
[0034] As used herein, the phrase "inhibiting tumor growth" includes any measurable reduction in tumor growth, including, for example, inhibition of tumor growth by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 99%, or 100%.
[0035] The term "effective amount", "pharmacologically effective amount" or "effective dose" is defined as an amount sufficient to achieve or at least partially achieve the desired effect. A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is a drug amount that, when used alone or in combination with other therapeutic agents, demonstrates disease regression, an increase in the frequency and duration of disease-free periods, or promotes the prevention of disorders or injuries caused by the disease, as evidenced by a reduction in the severity of disease symptoms. Therapeutically effective amounts or effective doses of drugs include "prophylactically effective amounts" or "prophylactically effective doses", which are drug doses that, when administered alone or in combination with other therapeutic agents to subjects at risk of developing the disease or who may suffer from the recurrence of the disease, hinder the occurrence or recurrence of the disease. The efficacy of therapeutic agents that promote disease regression or hinder the occurrence or recurrence of the disease can be evaluated using various methods known to those of ordinary skill in the art to which the invention belongs, for example, during clinical trials, it can be evaluated by analyzing the activity of the formulation in human subjects, in animal model systems that predict efficacy in humans, or in in vitro assays.
[0036] For example, an anticancer agent is a drug that promotes the regression of a subject's cancer. In some specific examples, a therapeutically effective amount of the drug promotes the regression of cancer until the cancer is eliminated. "Promoting cancer regression" refers to the pharmaceutically effective amount of the drug administered alone or in combination with an anti-neoplastic drug to bring about a tumor growth or size reduction, tumor necrosis, a reduction in the severity of at least one disease symptom, an increase in the frequency and duration of disease-free periods, the prevention of disease-induced disorders or injuries, or other improvements in the patient's disease symptoms. In addition, the terms "effective" and "effectiveness" include both treatment-related drug effectiveness and physiological safety. Drug effectiveness refers to the efficacy of a drug that can promote the regression of a patient's cancer. Physiological safety refers to the level of toxicity, or other adverse physiological effects (side effects) at the cell, organ and / or organism level caused by the administration of the drug.
[0037] For example, for tumor treatment, the therapeutically effective amount or effective dose of the drug hinders cell growth or tumor growth by at least about 20%, at least about 40%, at least about 60%, or at least about 80% compared to untreated subjects. In some specific examples, the therapeutically effective amount or effective dose of the drug completely hinders cell growth or tumor growth, that is, hinders cell growth or tumor growth by 100%. The ability of the inhibitor to hinder tumor growth can be evaluated using the analysis described below. Alternatively, the property of the composition can be evaluated by testing the ability of the inhibitor to hinder cell growth, and this hindrance can be measured in vitro by analysis known to those of ordinary skill in the art to which the present invention belongs. In other specific examples disclosed in this specification, tumor regression can be observed and can last for at least about 20 days, at least about 40 days, or at least about 60 days.
[0038] Some aspects of the invention relate to the diagnosis of cancer in a subject.
[0039] The term "diagnosis" as used in this specification refers to a method that can be used to determine or predict whether a patient will suffer from a given disease or condition. A person of ordinary skill in the art to which the present invention belongs can make a diagnosis based on one or more diagnostic markers (e.g., the expression level of c-Kit), wherein the presence, absence, amount, or change in amount of the diagnostic marker indicates the presence, severity, or absence of the state. In some specific examples, an increase in the expression of c-Kit in a biological sample from a subject is an indicative of a tumor. The term "diagnosis" does not refer to the ability to determine the presence or absence of a particular disease with 100% accuracy, nor does it even mean that a predetermined process or outcome is more likely to occur than if it were not the case. Instead, a person of ordinary skill in the art to which the present invention belongs should understand that the term "diagnosis" refers to the increased probability that a particular disease is present in a subject.
[0040] The term "diagnostic marker" (e.g., c-Kit expression) refers to a substance capable of separating tumors from normal cells for diagnosis, including organic biomolecules such as polypeptides, or nucleic acids (e.g., mRNA), lipids, glycolipids, glycoproteins, and sugars (monosaccharides, disaccharides, oligosaccharides, etc.), which are increased or decreased in tumor cells. For cancer, the diagnostic marker disclosed in the present specification may be a protein expressed from the c-Kit gene that is increased in tumor cells.
[0041] The composition for diagnosing cancer includes a preparation for measuring the expression level of the mRNA of the c-Kit gene or the amount of the expressed protein. These preparations include oligonucleotides having a complementary sequence to the c-Kit mRNA, primers or nucleic acid probes that specifically bind to the c-Kit mRNA, and antibodies or antigen-binding fragments thereof that specifically bind to the c-Kit protein (hereinafter referred to as anti-c-Kit antibodies) or antibody-drug conjugates (AntibodyDrug Conjugates) in which the anti-c-Kit antibody is connected to a drug via a linker.
[0042] The term "subject" used in this specification includes any human or non-human animal. The term "non-human animal" includes vertebrates, for example, mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0043] The term "c-Kit" belongs to the class III receptor tyrosine kinase (RTK), also known as the receptor of SCF.
[0044] "c-Kit" includes any variant or subtype of c-Kit naturally expressed by cells. Therefore, the anti-c-Kit antibody or antibody-drug conjugate disclosed in the present specification may cross-react with different subtypes of the same species (e.g., different subtypes of human c-Kit), or cross-react with c-Kit of species other than humans (e.g., mouse c-Kit). Alternatively, the anti-c-Kit antibody may be specific to human c-Kit and may not show cross-reactivity to other species. c-Kit, or any variant and subtype thereof, can be isolated or recombinantly produced from naturally expressed cells or tissues. The sequence of domains 1 to 3 of human c-Kit excluding 25 signal peptides (Q26 to D309) can be sequence number 12.
[0045] The term "antibody" is a term in the technical field to which the present invention belongs, and is used interchangeably in this specification to refer to a molecule having an antigen binding site that specifically binds to an antigen. The terms used in this specification include whole antibodies and any antigen binding fragment (i.e., "antigen-binding portion") or a single chain thereof. In one specific example, "antibody" refers to a glycoprotein or an antigen-binding portion thereof comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. In other specific examples, "antibody" refers to a short-chain antibody comprising a single variable domain, for example, a short-chain antibody comprising a VHH domain. Each heavy chain consists of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region. In a specific naturally occurring antibody, the heavy chain constant region consists of three domains CH1, CH2, and CH3. In a specific naturally occurring antibody, each light chain consists of a light chain variable region (abbreviated as VL) and a light chain constant region. The light chain constant region consists of one domain CL.
[0046] The VH and VL regions can be further subdivided into hypervariable regions called framework regions (FRs), which are interspersed with further preserved regions, called complementary determining regions (CDRs). Each VH and VL consists of three CDRs and four FRs, which are arranged from the amino acid terminus to the carboxyl terminus in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of an immunoglobulin to host tissues or factors, including various cells of the immune system (such as effector cells) and the first component (C1q) of the classical complement system.
[0047] The antibody may have any type of immunoglobulin molecule (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any type (e.g., IgD, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subtype (e.g., IgG1, IgG2, IgG3, and IgG4 in humans; and IgG1, IgG2a, IgG2b, and IgG3 in mice). Immunoglobulins, such as IgG1, exist in several allotypes, which differ from each other by at most a few amino acids. The antibodies disclosed in this specification may be derived from any of the conventionally known isotypes, types, subtypes, or allotypes. In a specific embodiment, the antibodies disclosed in this specification are of IgG1, IgG2, IgG3, or IgG4 subtypes or any hybrid thereof. In a specific embodiment, the antibody is an antibody of the human IgG1 subtype or the human IgG2 or human IgG4 subtype.
[0048] "Antibody" includes, for example, naturally occurring antibodies and non-naturally occurring antibodies; monoclonal antibodies and polyclonal antibodies; chimeric antibodies and humanized antibodies; human antibodies and non-human antibodies, fully synthetic antibodies; short chain antibodies; monospecific antibodies; multispecific antibodies (including bispecific antibodies); tetrameric antibodies comprising two heavy chain and two light chain molecules; antibody light chain monomers; antibody heavy chain monomers; antibody light chain dimers; antibody heavy chain dimers; antibody light chain-antibody heavy chain pairs; intrabodies; bispecific antibodies; monovalent antibodies; camelized antibodies; affibodies; anti-idiotypic (anti-Id) antibodies (such as anti-anti-Id antibodies), and single domain antibodies (sdAbs) comprising binding molecules composed of monomeric variable antibody domains (e.g., VH domains or VL domains) that are capable of sufficient antigen binding (Harmen MM and Haard HJ Appl Microbiol Biotechnol. 77(1):13-22 (2007)).
[0049] The term "antigen-binding portion" or "antigen-binding fragment" of an antibody as used in this specification refers to one or more antibody fragments that retain the ability to specifically bind to an antigen (such as domain 2 / 3 of human c-Kit). These "fragments" are, for example, about 8 to about 1500 amino acids in length, suitably about 8 to about 745 amino acids in length, more suitably about 8 to about 300, for example about 8 to about 200 amino acids, or about 10 to about 50 or 100 amino acids in length. It has been found that the antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. Examples of binding fragments included in the term "antigen-binding portion" or "antigen-binding fragment" of an antibody, for example, an anti-c-Kit antibody disclosed in the present specification include: (i) a Fab fragment, a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody and disulfide-linked Fvs (sdFv); (v) a dAb fragment consisting of a VH domain (Ward et al., (1989) Nature 341:544-546); and (vi) an isolated complementarity determining region (CDR) or (vii) a combination of two or more isolated CDRs that can be selectively linked by a synthetic linker, but are not limited thereto. In addition, VL and VH, which are two domains of the Fv fragment, are encoded by separate genes, but they can be connected by synthetic linkers using recombinant methods so that the VL and VH regions become a single protein chain (called short-chain Fv (scFv)) that is paired to form a monovalent molecule (for example, see Bird et al., (1988) Science 242: 423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). These short-chain antibodies are also included in the term "antigen-binding portion" or "antigen-binding fragment" of the so-called antibody. These antibody fragments are obtained using existing techniques known to those of ordinary skill in the art to which the present invention belongs, and the fragments are screened for usefulness in the same manner as intact antibodies. The antigen-binding portion can be produced by recombinant DNA technology, or by enzymatic or chemical cleavage of intact immunoglobulins.
[0050] The terms "variable region" or "variable domain" used in this specification are generally used interchangeably in the art to which the invention belongs. The variable region refers to a typical part of an antibody, usually a part of a light chain or a heavy chain, typically about the amino-terminal 110 to 120 amino acids in a mature heavy chain and about 90 to 115 amino acids in a mature light chain, which are very different from the antibody sequence and are used because of the binding and specificity of a specific antibody to its specific antigen. The sequence variability is concentrated in a region called the complementarity determining region (CDR), and further highly conserved regions in the variable domain are called framework regions (FR).
[0051] The CDRs of the light and heavy chains are considered to be primarily responsible for the interaction and specificity of the antigen and antibody. In a specific embodiment, the variable region is a human variable region. In a specific embodiment, the variable region includes a rodent or mouse CDR and a human framework region (FR). In a specific embodiment, the variable region is a primate (e.g., non-human primate) variable region. In a specific embodiment, the variable region includes a rodent or mouse CDR and a primate (e.g., non-human primate) framework region (FR).
[0052] The term "heavy chain" as used in this specification, when used in connection with antibodies, may refer to any of the different types, based on the amino acid sequence of the invariant domain, for example, alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ), which are subtypes of IgG, including, for example, IgG1, IgG2, IgG3 and IgG4, to produce IgA, IgD, IgE, IgG and IgM types of antibodies, respectively.
[0053] When the term "light chain" used in this specification is used in connection with an antibody, it can refer to any of different types, such as kappa (κ) and lambda (λ), based on the amino acid sequence of the invariant domain. Light chain amino acid sequences are well known in the art to which the present invention belongs. In a specific embodiment, the light chain is a human light chain.
[0054] The terms "VL" and "VL domain" are used interchangeably and refer to the light chain variable region of an antibody.
[0055] The terms "VH" and "VH domain" are used interchangeably and refer to the heavy chain variable region of an antibody.
[0056] The terms "constant region" or "invariant domain" used in this specification are used interchangeably and have the general meaning in the technical field to which the present invention belongs. The invariant domain is the part of the antibody, for example, the carboxyl terminal part of the light chain and / or the heavy chain, which, although not directly involved in the binding of the antibody to the antigen, can exhibit various effector functions such as interaction with Fc receptors. Compared with the immunoglobulin variable domain, the constant region of the immunoglobulin molecule generally has a more conserved amino acid sequence.
[0057] "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of the heavy chain of an antibody that mediates the binding of host tissues or factors to immunoglobulins, including binding to Fc receptors located on various cells of the immune system (such as effector cells) or the first component (C1q) of the orthodox complement system. Thus, the Fc region includes the constant region of an antibody except for the first constant region immunoglobulin domain (e.g., CH1 or CL). In IgG, IgA, and IgD antibody isotypes, the Fc region includes two identical protein fragments derived from the second (CH2) and third (CH3) constant domains of the two heavy chains of the antibody; IgM and IgE Fc regions include three heavy chain constant domains (CH domains 2 to 4) in each polypeptide chain. For IgG, the Fc region includes immunoglobulin domains Cγ2 and Cγ3 and the hinge between Cγ1 and Cγ2. The boundaries of the Fc region of an immunoglobulin heavy chain vary, but the Fc region of a human IgG heavy chain is generally limited to extending from an amino acid residue at position C226 or P230 (or an amino acid between two of them) to the carboxyl terminus of the heavy chain, wherein the numbering follows the EU index (EU Index), such as Kabat. The CH2 domain of the human IgG Fc region extends from about amino acid 231 to amino acid 340, and the CH3 domain is located on the C-terminal side of the Cm domain in the Fc region, i.e., it extends from about amino acid 341 of IgG to about amino acid 447. The Fc region may be a self-sequence Fc containing any allotypic variant, or a variant Fc (e.g., a non-naturally occurring Fc). In addition, Fc refers to a region that is processed in a separate state, or refers to a region associated with an Fc protein-containing polypeptide, also referred to as an "Fc fusion protein" (such as an antibody or immunoadhesion), such as a "binding protein including an Fc region", etc.
[0058] "Hinge", "hinge domain" or "hinge region" or "antibody hinge region" refers to the domain of the heavy chain constant region that connects the CH1 domain to the CH2 domain and includes the upper, central, and lower portions of the hinge (Roux et al. J. Immunol. 1998 161: 4083). The hinge changes the level of flexibility between the binding region and the effector region of the antibody, and provides a site for intermolecular disulfide bonds between the two heavy chain constant regions. The sequences of wild-type IgG1, IgG2, IgG3, and IgG4 hinges are known in the art to which the present invention belongs (e.g., see Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; Vidarsson G. et al., Front Immunol. 5: 520 (October 20, 2014, published online)).
[0059] The “isotype” used in the present specification refers to the antibody type encoded by the heavy chain constant region gene (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE antibodies).
[0060] "Allotype" refers to naturally occurring variants within a specific isotype group that differ in a few amino acids (e.g., see Jefferis et al. (2009) mAbs 1:1). The antibodies presented in this specification may have any allotype. Allotypes of IgG1, IgG2, IgG3, and IgG4 are known in the art to which the present invention belongs (e.g., see Kabat EA et al., (1991) (homologous); Vidarsson G. et al., Front Immunol. 5:520 (October 20, 2014 online); and Lefranc MP, mAbs 1:4, 1-7 (2009)).
[0061] The terms "antibody that recognizes an antigen" and "antigen-specific antibody" are used interchangeably with the term "antibody that specifically binds to an antigen" in this specification.
[0062] As used herein, an "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to c-Kit is substantially free of antibodies that specifically bind to antigens other than c-Kit). However, an isolated antibody that specifically binds to an epitope of c-Kit may have cross-reactivity to other c-Kit proteins from different species.
[0063] "Binding affinity" generally refers to the total strength of non-covalent interactions between a single binding site of a molecule (such as an antibody) and its binding partner (such as an antigen). Unless otherwise specified, "binding affinity" as used in this specification refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (such as an antibody and an antigen). The affinity of molecule X for partner Y can generally be represented by a dissociation constant (KD). Although not limiting, affinity can be measured and / or displayed in a variety of ways known in the art to which the invention belongs, including equilibrium dissociation constant (KD) and equilibrium association constant (KA). KD is calculated from the ratio of koff / kon and expressed as molar concentration (M), and KA is calculated from the ratio of kon / koff. Kon, for example, refers to the binding rate constant of an antibody to an antigen, and koff, for example, refers to the dissociation rate constant of an antibody to an antigen. Kon and koff can be determined by techniques known to those of ordinary skill in the art to which the invention belongs, such as immunoassays (such as enzyme-linked immunosorbent assay (ELISA)), Kinetic Exclusion Analysis
[0064] The terms "specific binding", "specific recognition", "specific binding", "selective binding" and "selective binding" used in this specification are similar to terms associated with antibodies and are terms related to molecules (such as antibodies) that bind to antigens (such as epitopes or immune complexes), and these bindings are as understood by ordinary technicians in the technical field to which the present invention belongs. For example, when using immunoassays, When determining molecules that specifically bind to an antigen using the Sapidyne 3000 instrument (manufacturer: Sapidyne Instruments, Boise, ID, USA) or other assays known in the art to which the present invention pertains, they are generally capable of binding to other peptides or polypeptides with lower affinity.
[0065] Antibodies are typically expressed by 10 -5 Up to 10 -11 Dissociation constants below 10 M reflect high affinity and specific binding to the cognate antigen. -4A KD of M is generally considered to represent nonspecific binding. An antibody that "binds specifically" to an antigen is one that binds to the antigen with high affinity and to substantially the same antigen, which means, for example, that the antibody binds to the antigen by immunoassay (e.g., ELISA) or in a pre-determined antigen. When determined by surface plasmon resonance (SPR) technology in the 2000 instrument, it has a 10 -7 M or less, preferably, 10 -8 M or less, more preferably, having 10 -9 M or less, more preferably, having 10 -10 Below M or 10 -11 With a KD below 1 M, this will not bind with high affinity to irrelevant antigens.
[0066] The term "antigen" used in this specification refers to any natural or synthetic immunogenic substance, such as a protein, peptide or hapten. The antigen may be c-Kit or a fragment thereof.
[0067] "Epitope" as used in this specification is a term in the technical field of the present invention, and refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be, for example, a continuous (contiguous) amino acid of a polypeptide (linear or continuous epitope), or an epitope can be, for example, a polypeptide or a synthesis of two or more non-continuous regions of a polypeptide (stereoscopic, non-linear, discontinuous or non-continuous epitope). Although not always the same, epitopes formed by continuous amino acids are typically retained when exposed to a denaturing solvent, while epitopes formed by three foldings are typically lost when treated with a denaturing solvent. An epitope includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20 amino acids in a typical unique spatial conformation. Methods for determining the epitope coupled by a given antibody (i.e., epitope mapping) are widely known in the art to which the present invention belongs, and include, for example, immunoblotting and immunoprecipitation analysis, testing the reactivity between overlapping or continuous peptides (e.g., c-Kit domains 2 and 3) and a given antibody (e.g., anti-c-Kit antibody). Methods for determining the spatial conformation of an epitope include techniques in the art to which the present invention belongs and disclosed in this specification, for example, X-ray crystallography, two-dimensional nuclear magnetic resonance, and HDX-MS (see, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996)).
[0068] With respect to two or more antibodies, the term "binding to the same epitope" means that the antibody binds to the same fragment of amino acid residues when determined by a predetermined method. Techniques for determining whether an antibody binds to the "same epitope on c-Kit" as the antibodies proposed in this specification include, for example, epitope mapping methods, such as X-ray analysis of crystals of antigen: antibody complexes and hydrogen / deuterium exchange mass spectrometry (HDX-MS) that provide atomic resolution of the epitope. Other methods monitor the binding of antibodies and antigen fragments or mutant variants of the antigen, in which the loss of binding caused by the modification of amino acid residues within the antigen sequence is primarily regarded as a marker of the epitope component. In addition, computer combinatorial methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from a combinatorial phage display peptide library. Antibodies with the same VH and VL or the same CDR1, 2 and 3 sequences are expected to bind to the same epitope.
[0069] An antibody that "cross-competes with other antibodies for binding to a target" refers to an antibody that blocks the binding of the remaining antibodies to the target (partially or completely). Whether two antibodies compete with each other for binding to the target, that is, whether one antibody blocks the binding of the remaining antibodies to the target, and the degree of blockage can be determined using known competition experiments. In a specific embodiment, the antibody competes in the binding of other antibodies to the target, blocking the binding by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of blockage or competition may vary depending on whether the antibody is a "blocking antibody" (i.e., a low-temperature antibody that is first incubated with the target). Competition analysis can be performed according to, for example, Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006; doi: 10.1101 / pdb.prot4277 or according to Chapter 11 of "Using Antibodies" by Ed Harlow and David Lane (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 1999). Competing antibodies bind to the same epitope, overlapping epitopes, or adjacent epitopes (e.g., by steric hindrance).
[0070] The term "control antibody" or "reference antibody" refers to an antibody used as a reference for analyzing competing antibodies binding to the same epitope, overlapping epitope, or adjacent epitope, in which the competing antibodies cross-compete for binding to the epitope.
[0071] Other competitive binding assays include: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme-linked immunosorbent assay (EIA), sandwich competition assay (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988)); solid phase direct labeled RIA using 1-125 label (see Morel et al., Mol. Immunol. 25(1):7 (1988)); solid phase direct biotin-avidin EIA (see Cheung et al., Virology 176:546 (1990)); and direct labeling RIA (see Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).
[0072] c-Kit consists of five extracellular domains, which consist of cytoplasmic kinase domains, including ATP-binding (TK1) and phosphotransferase (TK2) domains split by IgG like repeats, juxtamembrane and kinase insert. Upon ligand binding, c-Kit is activated by autophosphorylation through ligand-mediated dimerization. Ultimately, signal transduction mediators including Src, PI3K, STAT1 and JAK2 are recruited to regulate various cell-specific responses such as proliferation, survival and motility. In addition, it is known that overexpression of RTKs spontaneously activates cell growth in a ligand-independent manner. Overexpression and activation of c-Kit have been reported in various cancers including GBM, astrocytoma, germ cell and small cell lung cancer (SCLC), and are associated with poor prognosis.
[0073] The 2G4 antibody is a fully human anti-c-Kit antibody (anti-c-Kit antibody) that blocks SCF binding by binding to domain 2 / 3 of c-Kit, thereby exhibiting a c-Kit inhibitory effect. The specific c-Kit binding site of 2G4 confirmed the 2G4 / c-Kit composite docking model (J.-O. Kim et al., International Journal of Biological Macromolecules 159 (2020) 66-78), which is incorporated herein by reference.
[0074] In order to understand the molecular mechanism of 2G4 antibody, molecular docking analysis of the crystal structure of 2G4Fab and c-Kit (PDB ID: 2E9W) was performed using the HADDOCK / ZDOCK program. Residues 26-309 (D1-D3 region, sequence number 12) of c-Kit were used for docking calculations as described below.
[0075] First, blind docking calculations were performed using ZDOCK. The 10 model structures with the highest ZDOCK scores generally indicated that the CDR regions of 2G4Fab interacted with the D2 and D3 regions of c-Kit (D113-D309; sequence number 11). Based on the model structure of the 2G4 Fab:c-Kit complex, five residues (R122, Y125, R181, K203, and K205) were selected from the c-Kit D2 region (sequence number 9), and five residues (S240, S241, Y243, N260, and W262) were selected from the c-Kit D3 region (sequence number 10). The selected residues are expected to be responsible for 2G4. Next, 10 mutant c-Kit proteins were generated, and the binding affinity of 2G4 was compared with that of wild-type and mutant c-Kit proteins using ELISA ( Figures 14a to 14c ). ELISA results showed that the R122, Y125, R181, K203, K205, S261 and H263 residues of c-Kit were important for binding to 2G4.
[0076] A second docking calculation was performed using HADDOCK. The major residues of c-Kit confirmed by mutagenesis and ELISA analysis and all residues constituting the CDR of 2G4 were used as constraints. The docking model calculated by HADDOCK showed that the relative orientation and binding interface between 2G4 and c-Kit (i.e., the CDR loops of 2G4 and the D2 / D3 regions of c-Kit) were similar to the model calculated by ZDOCK. In the structural model of the 2G4 Fab:c-Kit complex with the highest score, it was confirmed that the heavy chain of 2G4 was closely associated with the D2-D3 region of c-Kit ( Fig.14dSpecifically, the binding interface between 2G4 Fab and c-Kit is mainly formed by electrostatic interactions between the heavy chain CDR of 2G4 and the D2 region of c-Kit. It was shown that the basic amino acids of c-Kit including R122, R181, K203 and R205 interact with the negatively charged residues of 2G4 (D74H, E119H, D120H, E123H and D126H) ( Fig.14e Additional interactions between S261 and H263 of the D3 region of c-Kit and the light chain residues (D82L, Q118L, T119L) of 2G4 also contribute to the formation of the complex ( Fig.14e ).
[0077] Through the docking calculation, it was demonstrated that 2G4 binds to R122, Y125, R181, K203, R205, S261 and H263 of the D2 / 3 region of c-Kit.
[0078] Therefore, the present invention provides an antibody-drug conjugate in which the antibody or its antigen-binding fragment specifically binds to c-Kit. In a specific embodiment of the antibody-drug conjugate, the antibody or its antigen-binding fragment specifically binds to domains 1-3 of human c-Kit (sequence number 12), more specifically, to domains 2 / 3 of human c-Kit (sequence number 11), further specifically, to the R122 to R205 region of domain 2 of human c-Kit (sequence number 9) and the S240 to H263 region of domain 3 (sequence number 10), most specifically, to the epitopes of R122, Y125, R181, K203, R205, S261 and H263 of domain 2 / 3 of human c-Kit.
[0079] The term "monoclonal antibody" as used in this specification refers to an antibody that exhibits a single binding specificity and affinity for a specific epitope or a composition of antibodies in which all antibodies exhibit a single binding specificity and affinity for a specific epitope. Therefore, the term "human monoclonal antibody" refers to an antibody or antibody composition that exhibits a single binding specificity and has variable and selective constant regions derived from human germline immunoglobulin sequences. In a specific example, a human monoclonal antibody is produced by a hybridoma comprising a B cell obtained from a transgenic non-human animal (e.g., a transgenic mouse) having a genome of a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
[0080] The term "recombinant human antibody" includes all human antibodies prepared, expressed, generated or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal to human immunoglobulin genes or hybridomas prepared therefrom, (b) antibodies isolated from host cells transformed to express antibodies, for example, antibodies isolated from transfectomas, (c) antibodies isolated from recombinant, combinatorial human antibody libraries, and (d) antibodies prepared, expressed, generated or isolated by any other means accompanied by splicing of human immunoglobulin gene sequences directed against other DNA sequences. These recombinant human antibodies are encoded by germline genes, but include variable and constant regions that utilize specific human germline immunoglobulin sequences, such as those that include subsequent rearrangements and mutations that occur during antibody maturation. As is known in the art to which the present invention belongs (e.g., see Lonberg (2005) Nature Biotech. 23 (9): 1117-1125), the variable region comprises an antigen binding domain, which is encoded by various genes that are rearranged to form specific antibodies against foreign antigens. In addition to rearrangement, the variable region can be further modified by multiple single amino acid changes (somatic mutations or hypermutations) to increase the affinity of the antibody for foreign antigens. The constant region will change in further response to the antigen (i.e., isotype switching). Therefore, the nucleic acid molecule that encodes light chain and heavy chain immunoglobulin polypeptides in response to an antigen and is rearranged and somatically mutated may not have sequence identity with the original nucleic acid molecule, but is substantially identical or similar (i.e., has at least 80% identity).
[0081] "HuMAb" refers to antibodies whose framework and CDR regions all have variable regions derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The antibodies proposed in this specification may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations induced by random or site-specific mutations in vitro or introduced by somatic mutations in vivo). However, the term "human antibody" does not include antibodies whose CDR sequences derived from the germline of another mammalian species (such as mice) are grafted to human framework sequences. The terms "human" antibody and "complete human" antibody are used as synonyms.
[0082] The term "humanized antibody" refers to an antibody in which part, most or all of the amino acids outside the CDR domain of a non-human antibody are replaced by corresponding amino acids derived from human immunoglobulins. In a specific example of a humanized form of an antibody, part, most or all of the amino acids outside the CDR domain are replaced by amino acids derived from human immunoglobulins, and part, most or all of the amino acids in one or more CDR regions remain unchanged. Amino acid addition, deletion, insertion, substitution or modification is acceptable as long as the ability of the antibody to bind to a specific antigen is not eliminated. A "humanized" antibody has an antigen specificity similar to that of the original antibody.
[0083] A "chimeric antibody" refers to an antibody whose variable region is derived from one species and whose constant region is derived from another species, for example, an antibody whose variable region is derived from a mouse antibody and whose constant region is derived from a human antibody.
[0084] The term "cross-reactivity" as used in this specification refers to the ability of the antibodies presented in this specification to bind to c-Kit from different species. For example, an antibody presented in this specification that binds to human c-Kit may also bind to c-Kit from other species (e.g., mouse c-Kit). These cross-reactivities can be determined by detecting specific reactivity with purified antigens in binding assays (e.g., SPR, ELISA), or by detecting binding or functional interaction with cells that physiologically express c-Kit. Methods for determining cross-reactivity include standard binding assays disclosed in this specification, for example, using 2000SPR instrument (manufacturer: Biacore AB, Uppsala, Sweden) Surface plasmon resonance (SPR) analysis, or flow cytometry techniques.
[0085] The term "conservative amino acid substitution" refers to the substitution of an amino acid residue by an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains are defined in the technical field to which the present invention belongs. These families include: amino acids having basic side chains (e.g., lysine, arginine, histidine); acidic side chains (e.g., aspartic acid, glutamic acid); uncharged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan); non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine); β-branched side chains (e.g., threonine, valine, isoleucine); and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In a specific embodiment, an expected non-essential amino acid residue in an anti-c-Kit antibody is substituted by another amino acid residue from the same side chain family. Methods for identifying conservative nucleotide and amino acid substitutions that do not abolish antigen binding are well known in the art to which the present invention belongs (e.g., see Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10): 879-884 (1999); and Burks et al. Proc. Natl. Acad. Sci. USA 94: 412-417 (1997)).
[0086] The term "substantial homology" means that two polypeptides or their designated sequences are identical when optimally aligned and compared, where at least about 80%, at least about 90% to 95%, or at least about 98% to 99.5% of the amino acids have appropriate amino acid insertions or deletions.
[0087] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap (i.e., % homology = # of identical positions / total # of positions x 100). Comparison of sequences and determination of percent identity between two sequences can be determined using a mathematical algorithm as described in the following non-limiting examples.
[0088] The percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm integrated into the GAP program of the GCG software package (available at http: / / www.gcg.com), using either the Blossum 62 matrix or the PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0089] The nucleic acid and protein sequences presented in this specification can be used as "query sequences" for searching in public databases, for example, to identify related sequences. These searches can be performed using the NBLAST and XBLAST programs (version 2.0) of the literature (Altschul, et al. (1990) J. Mol. Biol. 215: 403-10). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, word length = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules presented in this specification. BLAST protein searches can be performed with the XBLAST program, score = 50, word length = 3 to obtain amino acid sequences homologous to the protein molecules presented in this specification. In order to obtain gapped alignments for comparison purposes, Gapped BLAST can be used as described in the literature (Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of each program (eg, XBLAST and NBLAST) can be used (see worldwideweb.ncbi.nlm.nih.gov).
[0090] The term "connected" as used in this specification refers to the joining of two or more molecules. The connection can be covalent or non-covalent. The connection can also be genetic (i.e., recombinant fusion) connection. These connections can be achieved using various techniques recognized in the art to which the present invention belongs, such as chemical coupling and the production of recombinant proteins.
[0091] The term "antibody-drug conjugate" as used in this specification refers to the connection of an antibody or its antigen-binding fragment with another agonist, such as an anticancer agent, a chemotherapeutic agent, a toxin, an immunotherapeutic agent, an imaging probe, a spectroscopic probe, etc. These connections can be interactions through covalent bonds or non-covalent interactions, such as interactions through electrostatic forces. Various joints known in the relevant technical field can be used to form antibody-drug conjugates. In addition, antibody-drug conjugates can be provided in the form of fusion proteins, which can be expressed from polynucleotides encoding antibody-drug conjugates. In this specification, "fusion protein" originally refers to a protein produced by connecting two or more genes or gene fragments encoding separate proteins (including peptides and polypeptides). Translation of the fusion gene results in a single protein with functional properties derived from each original protein.
[0092] The term "spacer" as used herein refers to a substance that has the function of preventing the aggregation of the antibody-drug conjugate in the bloodstream and imparting stability in the bloodstream and targeted pharmacokinetic properties.
[0093] The term "linker" as used in this specification refers to any chemical part that can connect an antibody, antibody fragment (e.g., antigen binding fragment) or functional equivalent to another part, such as a drug part. Under conditions where the compound or antibody is still active, the linker may be sensitive to cleavage, such as acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage (cleavable linker). As another approach, the linker may be substantially resistant to cleavage (e.g., a stable linker or a non-cleavable linker). In some specific examples, the linker is a pre-charged linker, a hydrophilic linker, or a dicarboxylic acid-based linker.
[0094] The "non-cleavable linker" has relatively high plasma stability and is resistant to proteolysis. After being introduced into cells, the antibody must be decomposed before the drug can be released in the form of a complex with the linker, which has drug activity. The Thioether linker is a representative non-cleavable linker. After the antibody is non-selectively decomposed in the cell, the drug is detached and released. A non-lytic method is used.
[0095] "Cleavable linker" refers to a linker that can be cleaved in response to specific environmental factors and release the drug into the cytoplasm. The cleavable type includes the enzymatic type and the non-enzymatic type.
[0096] The enzymatic type is cleaved by enzymes such as cathepsin B, β-glucuronidase, phosphatase, pyrophosphatase, and sulfatase. The peptide linker is decomposed by protease, and there are protease inhibitors in plasma, so the plasma stability is high. As a protease for antibody-drug conjugates, cathepsin B is representative, and cathepsin B exists at high levels in tumor tissues to give tumor selectivity to antibody-drug conjugates. The peptide linker can be a dipeptide that mainly connects two amino acids. The β-glucuronic acid (β-glucuronide) linker is cleaved by β-glucuronidase, which is a glycolytic enzyme present in lysosomes. β-glucuronidase is overexpressed in some tumor cells to confer tumor specificity.
[0097] The non-enzymatic type has an acid-labile linker and an oxidation-reduction reaction linker.
[0098] Acid-labile linkers are low-stability linkers developed earlier, but are still in use. The most representative one is the hydrazone linker, which, after being internalized into tumor cells, is hydrolyzed in the weakly acidic environment of endosomes and lysosomes to release the drug.
[0099] The redox-reactive linker is typically a disulfide linker. After internalization, the linker is degraded by disulfide exchange or reducing agents such as glutathione, releasing the cytotoxic drug. The concentration of glutathione in tumor cells under hypoxia is about 1000 times higher than that in normal cells, which gives ADC tumor cell selectivity.
[0100] Pre-charged linkers are derived from charged cross-linking reagents that retain their charge after incorporation into the antibody drug conjugate. Examples of pre-charged linkers can be identified in U.S. Patent Publication No. 2009 / 0274713.
[0101] II. Antibody-drug conjugates (ADCs)
[0102] According to one aspect of the present invention, the present invention provides an antibody drug conjugate of the following formula 1:
[0103] Ab-(L) x -(D) y Formula 1
[0104] In the formula, Ab is an anti-c-Kit antibody or an antigen-binding fragment thereof that specifically binds to the epitope of human c-Kit in sequence number 9 and sequence number 10; L is a linker including a cleavable linker; D is a drug moiety; x is an integer from 1 to 8; and y is an integer from 1 to 8.
[0105] In some specific examples, the Ab is an antibody or an antigen-binding fragment thereof that specifically binds to one or more of R122, Y125, R181, K203, R205, S261 and H263 in sequence number 12. Preferably, the Ab is an antibody or an antigen-binding fragment thereof that specifically binds to R122, Y125, R181, K203, R205, S261 and H263 in sequence number 12. Wherein, sequence number 12 is the sequence of domains 1 to 3 of human c-Kit excluding 25 signal peptides (Q26 to D309), and the number of each amino acid is the number including 25 signal peptides. Thus, for example, the R122 represents the 97th amino acid sequence in sequence number 12, the Y125 represents the 100th amino acid sequence, and the remaining amino acids can also be interpreted in the same way.
[0106] In some specific examples, the antibody or its antigen-binding fragment competes with a reference antibody comprising heavy chain CDR1 of sequence number 1, heavy chain CDR2 of sequence number 2, heavy chain CDR3 of sequence number 3, light chain CDR1 of sequence number 4, light chain CDR2 of sequence number 5 and light chain CDR3 of sequence number 6 for binding to the epitope of human c-Kit at sequence number 9 and sequence number 10.
[0107] In some specific examples, the antibody or its antigen-binding fragment competes with a reference antibody comprising a heavy chain variable domain shown in sequence number 7 and a light chain variable domain shown in sequence number 8 for binding to the epitope of human c-Kit at sequence number 9 and sequence number 10.
[0108] In some specific examples, the antibody or its antigen-binding fragment includes the heavy chain CDR1 of sequence number 1, the heavy chain CDR2 of sequence number 2, the heavy chain CDR3 of sequence number 3, the light chain CDR1 of sequence number 4, the light chain CDR2 of sequence number 5 and the light chain CDR3 of sequence number 6.
[0109] In some specific examples, the antibody or antigen-binding fragment thereof includes a heavy chain variable domain shown by sequence number 7 and a light chain variable domain shown by sequence number 8.
[0110] Although not limited thereto, the antibody or antigen-binding fragment thereof may be a fragment in which one or two amino acids within the CDR are modified, deleted or substituted.
[0111] In some embodiments, the antibodies or antigen-binding fragments thereof may retain 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more identity within the heavy chain variable or light chain heavy chain regions.
[0112] In some embodiments, the antibody or antigen-binding fragment thereof can be a monoclonal antibody, a chimeric antibody, a humanized antibody, a human engineered antibody, a human antibody, a single-chain antibody (scFv), or an antibody fragment.
[0113] In some embodiments, the equilibrium dissociation constant K of the antibody or antigen-binding fragment thereof for human c-Kit is D The value can be 10 -11 M or less, specifically, for example, about 2.8237 (±0.9) × 10 -12 M.
[0114] The cleavable linker includes a linker selected from the group consisting of valine-citrulline-p-aminobenzylcarbamoyl (Val-Cit-PAB), alanine-phenylalanine-p-aminobenzylcarbamoyl (Ala-Phe-PAB), alanine-alanine-p-aminobenzylcarbamoyl (Ala-Ala-PAB), valine-alanine-p-aminobenzylcarbamoyl (Val-Ala-PAB), phenylalanine-lysine-p-aminobenzylcarbamoyl (Phe-Lys-PAB), alanine-alanine-glycine-p-aminobenzylcarbamoyl (Ala-Ala-Gly-PAB) and glycine-glycine-glycine-p-aminobenzylcarbamoyl (Gly-Gly-Gly-PAB) linkers, but is not limited thereto.
[0115] The L may include a spacer in a form that is linked to a polymer or not linked to a polymer.
[0116] According to one embodiment of the present invention, L is a linker comprising a linker derived from a cross-linking reagent, wherein the cross-linking reagent comprises a linker selected from (For example, ), as well as In one embodiment, when the linker comprises (For example, ) substituents, for example, the linker may include a disulfide bridge connecting two cysteine residues, such as a sulfur bridge ( Abzena) technology.
[0117] In the formula, the wavy line Indicates the site for other linkers or S or D binding.
[0118] The R can be hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, nitro, toluene, or halobenzene.
[0119] In some embodiments, L is a linker comprising a spacer in a form that is linked to a polymer or not linked to a polymer.
[0120] In some specific examples, the L comprises the structure of the following formula 2:
[0121] (L1) m -(S) n -(L2) p Formula 2
[0122] In the formula, L1 is a linker connecting the Ab and S or connecting Ab and L2; S is a spacer in the form of being connected to a polymer or not connected to a polymer; L2 is a cleavable linker; m is an integer from 0 to 8; n is an integer from 0 to 8; and p is an integer from 1 to 8.
[0123] In some specific examples, m is 1 to 4, n is 1 to 4, and p is 1 to 4.
[0124] In some embodiments, L1 comprises a linker selected from the group consisting of a cleavable linker, a non-cleavable linker, a hydrophilic linker, a procharged linker, and a dicarboxylic acid-based linker.
[0125] In some embodiments, L or L1 includes
[0126]
[0127] In the formula, the wavy line Indicates the site to which Ab, or S, L2, or D binds.
[0128] In some embodiments, L1 is a linker comprising a linker derived from a cross-linking reagent, wherein the cross-linking reagent comprises a linker selected from (For example, ), as well as Substituents in the group consisting of
[0129] In the formula, the wavy line Indicates the site where S binds.
[0130] The R can be hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, nitro, toluene, or halobenzene.
[0131] According to one embodiment of the present invention, the S (spacer) can be selected from as well as In the group composed of.
[0132] In the formula, the wavy line Indicates the site to which L1 or L2 binds. Preferably, the left wavy line side binds to L1, and the right wavy line side binds to L2.
[0133] In some embodiments, the S can be a spacer including aspartate, glutamate, or a combination thereof in a form that is linked to a polymer conjugate or not linked to a polymer.
[0134] As examples of the polymer, polyalkylene, polyalkylene glycol, polyvinylpyrrolidone, polyacrylate, polyoxazoline, polyvinylalcohol, polyacrylamide or polymethacrylamide, hydroxypropyl methacrylate (HPMA) copolymer, polyester, polyoxymethylene, polyorthoester, polycarbonate, poly(iminocarbonate), polyamide, copolymer of divinyl ether-maleic anhydride or styrene-maleic anhydride, polysaccharide, or polyglutamic acid may be used, but are not limited thereto.
[0135] In some embodiments, the polymer is polyethylene or polyethylene glycol.
[0136] The polyethylene glycol may include 10 to 30 ethylene glycol units (—O—CH 2 —CH 2 —), for example, 24 units.
[0137] According to one embodiment of the present invention, L comprises a linker selected from the group consisting of the following formulae 3 to 5:
[0138]
[0139]
[0140] In the formula, the wavy line Indicates the site to which Ab or D binds. Preferably, the left wavy line side binds to Ab and the right wavy line side binds to D.
[0141] As a drug moiety, preferably, D is a moiety selected from the group consisting of V-ATPase inhibitors, apoptosis promoters, Bcl2 inhibitors, MCL1 inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule inhibitors, auristatins, dolastatins, maytansinoids, MetAP (methionine aminopeptidase), inhibitors of nuclear export of protein CRM1, DPPIV inhibitors, proteasome inhibitors, inhibitors of phosphotransfer reactions in mitochondria, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, kinesin inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalators, DNA minor groove binders and DHFR inhibitors.
[0142] The drug moiety that modifies the predetermined biological response can be combined with the antibody, antibody fragment (e.g., antigen binding fragment) or functional equivalent of the present disclosure. The drug moiety should not be interpreted as being limited to classical chemotherapeutic agents. For example, the drug moiety can be a protein, peptide or polypeptide with the desired biological activity. Proteins as described above can include, for example, toxins such as abrin, ricin A, Pseudomonas exotoxin, cholera toxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet-derived growth factor, tissue-type plasminogen agonist, cytokine, apoptosis agonist, anti-angiogenesis agonist, or biological response modifiers such as lymphokines.
[0143] In some embodiments, a drug moiety, such as a cytotoxin, a drug (eg, an immunosuppressant), or a radiotoxin, is conjugated to an antibody, antibody fragment (eg, an antigen binding fragment), or functional equivalent of the present disclosure. Examples of cytotoxins include, but are not limited to, taxanes (e.g., see International (PCT) Patent Application Nos. WO 01 / 38318 and PCT / US03 / 02675), DNA-alkylating agents (e.g., CC-1065 analogs), anthracyclines, tubulin inhibitor (Tubulysin) analogs, duocarmycin analogs, auristatin E, auristatin F, maytansinoids, and cytotoxic agents containing a reactive polyethylene glycol moiety (e.g., see references [Sasse et al., J. Antibiot. (Tokyo), 53, 879-85 (2000)], [Suzawa et al., Bioorg. Med. Chem., 8, 2175-84 (2000)], [Ichimura et al., J. Antibiot. (Tokyo), 44, 1045-53 (1991)], [Francisco et al., Blood 2003 15; 102(4):1458-65], U.S. Patent Nos. 5,475,092, 6,340,701, 6,372,738, and 6,436,931, U.S. Patent Application Publication No. 2001 / 0036923A1, U.S. Patent Application Serial Nos. 10 / 024,290 and 10 / 116,053 in dispute, and International (PCT) Patent Application No. WO 01 / 49698), paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione dione), mitoxantrone, plicamycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin and their analogs or homologs.Therapeutic agents also include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothiophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin, anthracyclines (e.g., daunorubicin (formerly daunomycin and doxorubicin), antibiotics (e.g., dactinomycin D (formerly actinomycin), bleomycin, plicamycin and anthramycin (AMC)) and anti-mitotic agonists (e.g., vincristine and vinblastine) (e.g., see Seattle Genetics US20090304721).
[0144] Other examples of cytotoxins that can be bound to the antibodies, antibody fragments (antigen binding fragments) or functional equivalents of the present disclosure include duocarmycins, calicheamicins, maytansines, auristatins and their derivatives.
[0145] Various types of cytotoxins, linkers, and methods for coupling therapeutic agents to antibodies are well known in the relevant art, for example, see references [Saito et al., (2003) Adv. Drug Deliv. Rev. 55: 199-215]; [Trail et al., (2003) Cancer Immunol. Immunother. 52: 328-337]; [Payne, (2003) Cancer Cell 3: 207-212]; [Allen, (2002) Nat. Rev. Cancer 2: 750-763]; [Pastan and Kreitman, (2002) Curr. Opin. Investig. Drugs 3: 1089-1091]; [Senter and Springer, (2001) Adv. Drug Deliv. Rev. 53: 247-264].
[0146] The antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents disclosed herein may also be combined with radioactive isotopes to generate cytotoxic radiopharmaceuticals known as radioimmunoconjugates. Examples of radioisotopes that can be combined with antibodies for diagnosis or treatment include, but are not limited to, iodine-131, indium-111, yttrium-90, and ruthenium-177. Methods for preparing radioimmunoconjugates have been established in the relevant art. Commercially available radioimmunoconjugates include Zevalin and Ibrumomab. TM(IDEC Pharmaceuticals) and Bexxar TM (Corixa Pharmaceuticals), similar methods can be used to prepare radioimmunoconjugates using the antibodies disclosed in the present invention. In a specific aspect, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), which can be attached to the antibody via a linker molecule. Linker molecules such as those described above are generally known in the relevant technical field and are described in the literature [Denardo et al., (1998) Clin Cancer Res. 4 (10): 2483-90]; [Peterson et al., (1999) Bioconjug. Chem. 10 (4): 553-7]; and [Zimmerman et al., (1999) Nucl. Med. Biol. 26 (8): 943-50] (each incorporated by reference in its entirety).
[0147] In some embodiments, the D is a microtubule inhibitor (MTI) moiety.
[0148] Although not limited thereto, preferably the microtubule inhibitor may include a drug selected from the group consisting of SN-38 ((4S)-4,11-diethyl-4,9-dihydroxy-1,4-dihydro-3H,14H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14-dione), auristatin, dolastatin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), monomethyl dolastatin 10 (MMAD), or a combination thereof.
[0149] SN-38 blocks cell division by inhibiting DNA topoisomerase I. It is less potent and has fewer side effects than previously used drugs and can be used to increase the DAR to improve the side effect-to-side efficacy of antibody-drug conjugates.
[0150] Preferably, the antibody or antigen-binding fragment thereof specifically binds to an epitope of domain 2 / 3 of human c-Kit represented by sequence number 11 (i.e., D113 to D309), more preferably, specifically binds to an epitope of domain 2 of human c-Kit represented by sequence number 9 (i.e., R122 to R205) and / or domain 3 of human c-Kit represented by sequence number 10 (i.e., S240 to H263), and further preferably, specifically binds to one or more amino acid residues selected from the group consisting of R122, Y125, R181, K203, and R205 in sequence number 9 and / or one or more amino acid residues selected from the group consisting of S261 and H263 in sequence number 10.
[0151] In some specific examples, the antibody or its antigen-binding fragment competes with a reference antibody comprising a heavy chain variable domain shown in sequence number 7 and a light chain variable domain shown in sequence number 8 for binding to an epitope of domain 2 / 3 of human c-Kit of sequence number 11 (i.e., D113 to D309).
[0152] According to one embodiment of the present invention, the antibody drug conjugate is selected from the group consisting of the following formulae 6 to 8:
[0153]
[0154] as well as
[0155]
[0156] In the above formula, a is an integer of 1 to 8, and b and c are integers of 1 to 4, respectively.
[0157] According to other aspects of the invention, the present invention provides an antibody-drug conjugate selected from the group consisting of the following formulas 6 to 8:
[0158]
[0159]
[0160] In the formula, Ab is an antibody or an antigen-binding fragment thereof comprising the heavy chain CDR1 of sequence number 1, the heavy chain CDR2 of sequence number 2, the heavy chain CDR3 of sequence number 3, the light chain CDR1 of sequence number 4, the light chain CDR2 of sequence number 5 and the light chain CDR3 of sequence number 6; a is an integer from 1 to 8, and b and c are integers from 1 to 4, respectively.
[0161] In some embodiments, the antibody-drug conjugate has a structure of Formula 7, and b is 2.
[0162] In some embodiments, the antibody-drug conjugate has a structure of Formula 7, and b is 4.
[0163] III. Composition
[0164] According to another aspect of the present invention, the present invention provides a composition comprising an antibody drug conjugate or a pharmaceutically acceptable salt thereof.
[0165] In some embodiments, the composition is a pharmaceutical composition for cancer prevention or treatment.
[0166] According to yet another aspect of the present invention, the present invention provides a composition for use in therapy.
[0167] In some embodiments, the use is for the treatment of cancer.
[0168] According to yet another aspect of the present invention, the present invention provides use for preparing the pharmaceutical composition.
[0169] According to still another aspect of the present invention, the present invention provides a method for preventing or treating cancer, the method comprising the step of administering the composition to a subject in need of the composition.
[0170] The present specification discloses a method for treating a tumor (or cancer) in a subject, which comprises administering the antibody-drug conjugate or a pharmaceutically acceptable salt thereof to the subject. In a specific embodiment, the antibody-drug conjugate specifically binds to the c-Kit protein, thereby reducing the activity of c-Kit.
[0171] In some specific examples, the methods disclosed in this specification hinder and / or reduce tumor growth in a subject. In a specific example, tumor growth (e.g., tumor volume or weight) is reduced to at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% compared to a standard (e.g., a composition disclosed in this specification, e.g., a corresponding tumor volume or weight in a subject who has not received the antibody-drug conjugate). In some specific examples, the methods disclosed in this specification increase the average tumor growth retardation (TGI) to at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% compared to a standard (e.g., a composition disclosed in this specification, e.g., a corresponding frequency in a subject who has not received the antibody-drug conjugate). In some embodiments, administration of a composition disclosed herein (e.g., the antibody-drug conjugate) increases mean survival by at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or longer compared to a standard (e.g., a composition disclosed herein, e.g., a corresponding value in a subject not receiving the antibody-drug conjugate).
[0172] In some embodiments, the tumors that can be treated by the methods disclosed in this specification are derived from cancers that are typically responsive to existing anticancer agents, and cancers that are typically not responsive to existing anticancer agents. In some embodiments, the cancer is a solid tumor or a cancer with a hematological malignancy (liquid tumor).
[0173] Non-limiting examples of cancers in need of treatment include: squamous cell carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, gastrointestinal cancer, kidney cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrioma, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate cancer), thyroid cancer, pancreatic cancer, cervical cancer, gastric cancer, bladder cancer, hepatocellular carcinoma, breast cancer, colon cancer, and head and neck cancer (or carcinoma), germ cell tumors, pediatric sarcomas, nasal natural killer, melanoma (e.g., metastatic malignant melanoma, skin cancer, for example), or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial cancer, cancer of the cervix, vaginal cancer, cancer of the vulva, cancer of the esophagus, small intestine cancer, large intestine cancer, mast cell tumors, cancer of the endocrine system, cancer of the parathyroid glands, cancer of the adrenal glands, sarcomas of the soft tissues, cancer of the urethra, cancer of the sex organs, solid tumors of children, cancer of the ureter, cancer of the renal pelvis, tumor angiogenesis, pituitary adenoma, Kaposi's sarcoma, epithelial cancer, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers including those caused by asbestos, viral cancers or cancers of viral origin (e.g. human papillomavirus (HPV)-related or origin tumors leukemias, lymphomas, myeloblastic leukemias, myeloblastic leukemias (M1), myeloblastic leukemias (M2); with maturation of cells), panmyeloid leukemia (M3 or M3 variant [M3V]), chronic myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythrocytic leukemia (M6), megakaryocytic leukemia (M7), isolated granular sarcoma, and chloroma; lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), B-cell hematologic malignancies, such as B-cell lymphoma, T-cell lymphoma, lymphoblastoid lymphoma, monocytic B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) giant cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphocytic lymphoma, T-lymphocytic;and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphocytic lymphoma, post-transplant lymphoproliferative disorder, true organizing lymphoma, primary effusion lymphoma, B-cell lymphoma, lymphocytic lymphoma (LBL), lymphoid system hematopoietic tumors, acute lymphocytic leukemia, diffuse large B-cell B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse organizing lymphoma (DHL), immunoblastic giant cell lymphoma, precursor B-lymphocytic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sezary syndrome), and lymphoblastic lymphoma (LPL) associated with Waldenstrom's macroglobulinemia; myeloma, such as IgG myeloma, light chain myeloma, non-secretory myeloma, non-progressive myeloma (smoldering myeloma) (also known as smoldering myeloma), solitary plasmocytoma, and multiple myeloma, chronic lymphocytic leukemia (CLL), morphine cell lymphoma; mesenchymal tumors, including myeloid hematopoietic tumors, fibrosarcoma and rhabdomyomas; mesenchymal seminoma, teratoma, tumors including fibrosarcoma, rhabdomyomas and osteosarcoma; and other tumors including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular tumor and teratoma, lymphopoietic tumors, for example, T cells and T cell tumors, including but not limited to T cell disorders such as T-prolymphocytic leukemia (T-PLL), including small cell and brain cell types; T cell type large granular lymphocytic leukemia (LGL); a / d T-NHL hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head or neck cancer, kidney cancer, rectal cancer, thyroid cancer; acute myeloid lymphoma and any combination thereof.
[0174] According to one embodiment of the present invention, the cancer is one or more cancers selected from the group consisting of esophageal cancer, gastric cancer, gastrointestinal stromal tumors (GIST), colorectal cancer, rectal cancer, lung cancer, especially small cell lung cancer (SCLC), breast cancer, mast cell tumor and leukemia, especially acute myeloid leukemia (AML).
[0175] In some specific examples, the methods disclosed in this specification can also be used for the treatment of metastatic cancer, unresectable cancer, refractory cancer (e.g., cancer resistant to previous cancer therapies, e.g., immunotherapy, e.g., therapy that blocks PD-(L)1 antibodies), and / or recurrent cancer. In specific examples, the methods disclosed in this specification can be used for the treatment of recurrent cancer.
[0176] In some embodiments, the conventional cancer therapy of the methods disclosed in this specification includes chemotherapy, for example, it can be administered in combination with imatinib and other c-KIT pathway inhibitors.
[0177] In some specific examples, the methods disclosed in this specification effectively increase the survival duration of a subject (e.g., a tumor invaded). For example, when the survival duration of a subject is compared to a reference individual (e.g., a composition disclosed in this specification, e.g., other subjects not treated with the antibody-drug conjugate), it is increased to at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, or at least about 1 year or more. In another specific example, the methods disclosed herein extend the survival duration of a subject to a level longer than the survival duration of a reference subject (e.g., a composition disclosed herein, e.g., other subjects not treated with the antibody-drug conjugate) (about 1 month longer, about 2 months longer, about 3 months longer, about 4 months longer, about 5 months longer, about 6 months longer, about 7 months longer, about 8 months longer, about 9 months longer, about 10 months longer, about 11 months longer, or about 1 year longer).
[0178] In some specific examples, the method of the present invention increases the duration of survival without disease progression in the subject. For example, the duration of survival without disease progression in the subject is increased to at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, or at least about 1 year compared to a reference subject (e.g., a composition disclosed in this specification, e.g., other subjects not treated with the antibody-drug conjugate).
[0179] In some specific examples, the methods disclosed in this specification effectively increase the reaction rate in a group of subjects. For example, the reaction rate in a group of subjects is increased to at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99% or at least about 100% compared to a reference subject (e.g., a composition disclosed in this specification, e.g., other subjects not treated with the antibody-drug conjugate).
[0180] In some embodiments, the subject treated in the present method is a non-human animal, such as a rat or a mouse. In some embodiments, the subject treated in the present method is a human.
[0181] The present invention also includes methods for treating cancer in a subject in combination with other cancer preparations. In some specific examples, in the methods of the present invention, the useful antibody-drug conjugate can be used as a combination therapy, that is, it can be administered in combination with at least one other anticancer agent and / or immunomodulator, such as T cell stimulation (e.g., activation) preparation. In some specific examples, in the methods of the present invention, useful antibody-drug conjugates can be administered in combination with other compounds, drugs, and / or preparations for cancer treatment. These compounds, drugs, and / or preparations may include, for example, chemotherapeutic drugs, small molecule drugs, or antibodies that stimulate the immune response of cancer. In some specific examples, the methods disclosed in this specification are used in combination with standard treatments (e.g., surgery, radiation, and chemotherapy). In other specific examples, the methods disclosed in this specification are used as maintenance therapy, for example, a therapy to prevent tumor occurrence or recurrence.
[0182] In some embodiments, the antibody-drug conjugates disclosed herein can be used in combination with one or more additional cancer agents including immunotherapeutic agents, chemotherapeutic agents, targeted therapeutic agents, radiotherapeutic agents (radiotherapy), or any combination thereof.
[0183] Disclosed in this specification are compositions containing the antibody-drug conjugate disclosed in this specification with a desired degree of purity in a physiologically acceptable carrier, excipient or stabilizer (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). Acceptable carriers, excipients or stabilizers are non-toxic to the receptor at the dosages and concentrations used, and include: buffers, such as phosphates, citrates and other organic acids; antioxidants containing ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexahydroxyquaternary ammonium chloride; benzalkonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins Proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; other carbohydrates including monosaccharides, disaccharides, and glucose, mannose, or dextrins; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, such as or polyethylene glycol (PEG).
[0184] In some specific examples, the pharmaceutical composition includes an antibody-drug conjugate disclosed in this specification in a pharmaceutically acceptable carrier. In a specific specific example, the pharmaceutical composition includes an effective amount of the antibody-drug conjugate disclosed in this specification and one or more selectively added preventive or therapeutic agents in a pharmaceutically acceptable carrier. In some specific examples, the antibody-drug conjugate is the only active ingredient contained in the pharmaceutical composition. The pharmaceutical composition disclosed in this specification may be useful for reducing the activity of c-Kit, thereby treating cancer.
[0185] Pharmaceutically acceptable carriers used in parenteral preparations include aqueous carriers, non-aqueous carriers, antibacterial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending dispersants, emulsifiers, gold oxide ion blocking or chelating agents, and other pharmaceutically acceptable substances. Examples of aqueous carriers include sodium chloride injection, drip injection, isotonic glucose injection, sterile water injection, glucose and lactic acid drip injection. Non-aqueous carriers include fixed oils of plant origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antibacterial agents at bacteriostatic or fungistatic concentrations can be added to parenteral preparations packaged in high-dose containers, and they include phenol or cresol, mercury-containing substances, benzyl alcohol, chlorobutanol, methyl and propyl parabens, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and glucose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinyl pyrrolidone. Emulsifiers include polysorbate 80 ( 80). Metal ion blocking or chelating agents include EDTA. Pharmaceutical carriers also include ethanol, polyethylene glycol and propylene glycol in water-mixed carriers, sodium hydroxide, hydrochloric acid, citric acid or lactic acid for adjusting pH.
[0186] Pharmaceutical compositions can be formulated according to any route of administration for a subject. Specific examples of routes of administration include intranasal, oral, parenteral, intraspinal, intracerebroventricular, pulmonary, subcutaneous, or intraventricular routes. Parenteral administration characterized by subcutaneous, intramuscular or intravenous injection is also contemplated. Injectable substances can be prepared into liquid solutions or suspensions in conventional forms, and can be prepared into solid forms or emulsions suitable for becoming solutions or suspensions in liquids before injection. Injectable substances, solutions and emulsions also include more than one excipient. Suitable excipients are, for example, water, saline, glucose, glycerol or ethanol. In addition, if necessary, the pharmaceutical composition to be used may also include a small amount of non-toxic auxiliary substances, such as wetting or emulsifiers, pH buffers, stabilizers, solubility enhancers and other preparations, such as sodium acetate, sorbitol monolaurate, triethanolamine oleate and cyclodextrin.
[0187] Preparations for parenteral administration of antibody-drug conjugates include sterile solutions that can be injected directly, sterile dry soluble products that can be directly combined with solvents before use, such as lyophilized powders, sterile suspensions that can be injected directly, sterile dry insoluble products that can be directly combined with carriers before use, and sterile emulsions. The solution can be aqueous or non-aqueous.
[0188] The antibody-drug conjugates disclosed in this specification or their pharmaceutically acceptable salts can also be prepared to target specific tissues, receptors, or other body regions of the subject to be treated. Various targeting methods are known to those of ordinary skill in the art to which the present invention belongs. These targeting methods are considered to be used in the composition. Non-limiting examples of targeted approaches are found in U.S. Pat. Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874. In certain embodiments, the antibody-drug conjugate or a pharmaceutically acceptable salt thereof disclosed in the present specification can be used to treat cancer.
[0189] Compositions for in vivo administration can be sterilized, for example, by filtration through a sterile filtration membrane.
[0190] According to another aspect of the present invention, a composition for cancer diagnosis comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof is provided.
[0191] IX. Kit
[0192] In this specification, a kit comprising one or more antibody-drug conjugates disclosed in this specification or a pharmaceutically acceptable salt thereof is disclosed. In some specific examples, in this specification, one or more containers filled with one or more components of the composition disclosed in this specification including one or more antibody-drug conjugates disclosed in this specification or a pharmaceutically acceptable salt thereof, a drug package or a kit including selective instructions for use is disclosed. In some specific examples, the kit comprises a pharmaceutical composition disclosed in this specification and any preventive or therapeutic agent disclosed in this specification. In some specific examples, a composition for cancer diagnosis in which the kit comprises a composition disclosed in this specification and instructions for detection and / or diagnostic methods is disclosed.
[0193] In some embodiments, a method for providing information for cancer diagnosis is provided, the method comprising the step of treating an antibody drug conjugate or a pharmaceutically acceptable salt thereof to a sample separated from a subject.
[0194] X. Production method
[0195] The present specification discloses a method for producing one or more anti-c-Kit antibody drug conjugates disclosed in the present specification.
[0196] The conjugates disclosed in the present invention can be prepared by any method known in the relevant technical field, for example, by methods described in U.S. Patent Nos. 7,811,572, 6,411,163, 7,368,565, and 8,163,888, and U.S. Patent Nos. 2011 / 0003969, 2011 / 0166319, 2012 / 0253021, and 2012 / 0259100. All of the references to these patents and patent application publications are incorporated herein by reference.
[0197] In addition, various types of cytotoxins, linkers, and methods for coupling drugs to antibodies are well known in the relevant art, for example, see the literature (Saito et al., Adv. Drug Deliv. Rev. 55: 199-215 (2003); Trail et al., Cancer Immunol. Immunother. 52: 328-337 (2003); Payne, Cancer Cell 3: 207-212 (2003); Allen, Nat. Rev. Cancer 2: 750-763 (2002); Pastan and Kreitman, Curr. Opin. Investig. Drugs 3: 1089-1091 (2002); Senter and Springer, Adv. Drug Deliv. Rev. 53: 247-264 (2001)].
[0198] In some embodiments, the production method comprises linking (L1) to an antibody or antigen-binding fragment thereof (Ab) that specifically binds to human c-Kit m -(S) n -(L2) p -(D) q Steps:
[0199] In the formula, L1 is a linker connecting the Ab and S or connecting Ab and L2; S is a spacer in the form of being connected to a polymer or not connected to a polymer; L2 is a cleavable linker; D is a drug moiety; m is an integer from 0 to 8; n is an integer from 0 to 8; p is an integer from 1 to 8; and q is an integer from 1 to 8.
[0200] The definitions and related explanations of the terms are the same as those described in I. Definitions and II. Antibody-Drug Conjugate (ADC).
[0201] In some specific examples, the production method is a method for producing an anti-c-Kit antibody-drug conjugate, which includes the step of coupling an antibody or an antigen-binding fragment thereof comprising a heavy chain CDR1 of sequence number 1, a heavy chain CDR2 of sequence number 2, a heavy chain CDR3 of sequence number 3, a light chain CDR1 of sequence number 4, a light chain CDR2 of sequence number 5, and a light chain CDR3 of sequence number 6 to a linker (L)-drug (D), wherein L includes a cleavable linker.
[0202] In some embodiments, D is a microtubule inhibitor moiety.
[0203] In some specific examples, m is 1 to 4, n is 1 to 4, p is 1 to 4, and q is 1 to 8.
[0204] Effects of the Invention
[0205] The features and advantages of the present invention are summarized as follows:
[0206] (i) The present invention provides an antibody-drug conjugate comprising an antibody that specifically binds to human c-Kit, a cleavable linker, and a microtubule inhibitor moiety.
[0207] (ii) In addition, the present invention provides a pharmaceutical composition for cancer prevention or treatment comprising an antibody-drug conjugate as an active ingredient.
[0208] (iii) The antibody-drug conjugate of the present invention is characterized in that it retains potent anticancer activity to induce complete remission against c-Kit-positive and -negative cancer cell lines and / or imatinib-resistant cancer cell lines. BRIEF DESCRIPTION OF THE DRAWINGS
[0209] FIG1 shows a method for preparing ADCs using cleavable linkers. Figure 1a The linker-drug used in one embodiment is shown, Figure 1b Show Brief preparation process of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u).
[0210] Figure 2 The results of in vitro cell viability assays are shown to confirm the efficacy of the antibody-drug conjugates (ADCs) of the present invention in c-Kit-positive and negative cancer cell lines.
[0211] FIG. 3 shows the results of confirming the in vivo efficacy of the ADC of the present invention on GIST in mice (GIST T1 cells) ( Figure 3a PoC-DM1 results are shown; Figure 3b Show 003-1, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2 results; Figure 3c Show 004-2, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 results; Figure 3d The results of 003-2 and 2G4-MC-Val-Cit-PAB-MMAE are shown).
[0212] FIG. 4 shows the results of confirming the in vivo efficacy of the ADC of the present invention against GIST in mice (GIST-430 / 654 cells) ( Figure 4a Results for PoC-DM1 are shown; Figure 4b Show 003-1, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2 results; Figure 4c Show 004-2, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 results; Figure 4d Results for 003-2 and 2G4-MC-Val-Cit-PAB-MMAE are shown; Figure 4e Show 007-1, 2G4- -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2).
[0213] FIG. 5 shows the results of confirming the in vivo efficacy of the ADC of the present invention against SCLC in mice (SCLC-H526 cells) ( Figure 5a Results for PoC-DM1 are shown; Figure 5b Show 003-1, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2 results; Figure 5c Show 004-2, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 results; Figure 5d The results of 003-2 and 2G4-MC-Val-Cit-PAB-MMAE are shown).
[0214] Figure 6 The results of confirming the in vivo efficacy of the ADC of the present invention against mastocytoma in mice (HMC 1.2 cells) are shown.
[0215] Figure 7The results of confirming the efficacy of the ADC of the present invention upon tumor re-inoculation are shown.
[0216] Figure 8 The results of confirming the in vivo efficacy of the ADC of the present invention against acute myeloid leukemia (AML) in mice (Kasumi-1 cells) are shown.
[0217] FIG. 9 shows the results of confirming the in vivo efficacy of the ADC of the present invention against breast cancer in mice (MDA-MB-468 cells) ( Figure 9a Results for PoC-DM1 are shown; Figure 9b Show 003-1, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2 results; Fig.9c Show 004-2, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 results; Figure 9d The results of 003-2 and 2G4-MC-Val-Cit-PAB-MMAE are shown).
[0218] Fig.10 Shown are the results of a re-challenge analysis of small cell lung cancer (SCLC) in mice (SCLC-H526 cells) against the ADCs of the present invention.
[0219] Fig.11 The results of re-challenge analysis of mastocytoma in mice (HMC 1.2 cells) using the ADC of the present invention are shown.
[0220] Fig.12 The results of preliminary in vivo toxicity analysis of the ADC of the present invention when administered at a high concentration (10 mg / kg) are shown.
[0221] FIG. 13 shows the results of in vivo toxicity pre-analysis of the ADC of the present invention when administered at higher concentrations (20 / 40 / 60 mg / kg) ( Fig.13a 13a shows the results of 2G4 antibody; 13b shows the results of PoC-DM1; Fig.13c Show 003-1, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2 results; Fig.13d Show 004-2, 2G4 -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 results).
[0222] FIG14 shows the docking model of 2G4 Fab:c-Kit. Fig.14a)Summary of c-Kit mutants. Fig.14b and c) purified c-Kit wild-type and mutant proteins, serially diluted, and coated in 96-well plates. Binding of 2G4 was examined by enzyme-linked immunosorbent assay (ELISA). Fig.14d ) shows the structural model of the 2G4 Fab:c-Kit complex with the highest score calculated by HADDOCK. The heavy chain (H) variable (V) region and constant (C) region and the light chain (L) variable (V) region and constant (C) region of 2G4 are represented by VH, CH1, VL and CL, respectively. ( Fig.14e ) shows the interface between 2G4 and c-Kit as a stick. The residues in the D2 and D3 regions of c-Kit are represented by shaded sticks, respectively. DETAILED DESCRIPTION
[0223] The present invention is further described in detail below by way of examples. These examples are only used to further illustrate the present invention. According to the gist of the present invention, the scope of the present invention is not limited by these examples, which is obvious to those skilled in the art to which the present invention belongs.
[0224] Example
[0225] Preparation Example
[0226] Preparation Example 1. Preparation of anti-c-Kit antibody 2G4
[0227] Preparation Example 1-1. Preparation of immunized mice
[0228] 50 μg (per mouse) of recombinant c-Kit protein (cat#PKSH030939) purchased from Elabscience was mixed with an equal volume of complete Freund's Adjuvant (Sigma, USA) to prepare an emulsion. The emulsion prepared as described above was injected into the peritoneal cavity of 6 humanized NSG mice made by injection of 7-week-old female humanCD34+ cells. 50 μg of antigen was injected into each mouse in a total volume of 500 μl. After 1 week and 2 weeks, the mice were further injected with emulsions mixed with incomplete Freund's adjuvant (Sigma, USA) and antigens.
[0229] Preparation Example 1-2. Confirmation of Antibody Production
[0230] Blood was collected from the eyeball of the immunized mouse by the method and placed in a 1.5 ml microcentrifuge tube, then centrifuged at 13000 rpm for 10 minutes. The serum was separated and stored at -20 °C until the experiment of confirming antibody generation was performed. Enzyme immunoassay was performed using antigen protein to confirm antibody generation, and then the emulsion of incomplete Freund's adjuvant (Sigma, USA) and antigen was once again injected into the peritoneal cavity of the mouse before cell fusion 3 days later.
[0231] Preparation Example 1-3. Preparation of hybridoma
[0232] After confirming the production of antibodies, the mice were sacrificed. Splenocytes were isolated and fused with myeloma cells P3X63Ag 8.653 (ATCC CRL-1580) to prepare hybridomas.
[0233] Specifically, mouse P3X63Ag 8.653 cells were cultured in a culture plate using RPMI1640 medium supplemented with 10% fetal bovine serum. For cell fusion, P3X63Ag 8.653 cells were washed twice with serum-free RPMI1640 medium (Hyclone, USA) and adjusted to 1×10 7 Cell concentration. Mice were killed by cervical dislocation, and the spleen was removed and then placed in a mesh container (Sigma, USA) to separate the cells. After preparing a suspension of spleen cells, the suspension was washed by centrifugation. The spleen cell solution was exposed to Tris-NH4Cl (TRIS20.6g / L, NH4Cl 8.3g / L) to lyse red blood cells. The completely separated antibody-producing cells were centrifuged at 400×g for 5 minutes. Then, they were washed twice in serum-free medium and resuspended in 10 ml of medium. Lymphocytes were counted using a hemocytometer and 1×10 8 Mixed with P3X63Ag 8.653 cells at 1×10 (10:1) in serum-free medium.
[0234] Centrifuge at 400 × g for 5 minutes, then add 1 ml of solution using 50% (M / V) polyethylene glycol 1500 (Sigma, USA) heated at 37°C to mix for 1 minute. The fusion mixed solution prepared as described above was diluted with serum-free RPMI1640 and centrifuged at 400 × g for 3 minutes. Suspend cells in 35 ml of RPMI1640 selective culture medium supplemented with 20% fetal bovine serum and HAT (100 μM hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine). 100 μl of suspension was loaded onto a 96-well plate coated with feeder cells (macrophages isolated from the peritoneal cavity using RPMI1640) 1 day ago and incubated at 37°C, 5% CO2. After 5 days, the HAT culture medium was replaced every 2 to 3 days, and the cells were cultured for 14 days. After 14 days, the medium was replaced with RPMI1640 medium supplemented with 20% fetal bovine serum and HT (a medium in which 0.4 μM aminopterin was removed from HAT) for secondary culture.
[0235] Preparation Example 1-4. Selection and separation of antibody-producing fusion cells
[0236] The supernatant of the previously prepared fused cell culture fluid was collected and subjected to enzyme immunoassay to confirm whether specific antibodies were generated for the prepared antigen. The culture fluid of the fused cells showing a titration concentration of more than 4 times that of the negative control group was selected and transferred to a 24-well plate for culture. Further dilution was performed to allow 1 cell to enter each well in a 96-well plate (limiting dilution), and then the culture fluid was recovered, and the c-KIT protein used as an antigen was coated with 0.1 μg per well in a 96-well plate. Then, an enzyme immunoassay was performed, and fused cells producing 15 monoclonal antibodies (1C6, 1H2, 1A6, AFA, 2B3, 2G4, 4G5, 4C4, 4C7, 4D7, 1E1, 2H6, 1G3, 1A3, 1D3) were finally selected.
[0237] Preparation Example 1-5. c-KIT Antibody Screening
[0238] In order to confirm the c-KIT binding ability of the screened antibodies, surface plasmon resonance (SPR) was performed. Using SR7500DC (Reichert, USA), 20 μg of human c-Kit (elabscience, PKSH030939), 20 μg of mouse c-Kit (SB, Lot#LC05DE2304), and 20 μg of rat c-Kit (SB, Lot#LC06SE1787) used for antibody preparation were fixed on a PEG (Reichert, USA) chip. Then, the antibody was allowed to flow according to the concentration, and the affinity KD value for c-Kit was analyzed using the Scrubber2 program. The KD value is the value of kd divided by ka. The lower the value, the greater its binding ability to the object.
[0239] The results showed that the KD value of 2G4 antibody for human c-Kit was approximately 2.8237 (±0.9) × 10 -12 M, showing a stronger affinity. The highest affinity is for humans, followed by mice and rats.
[0240] The CDR sequences of the screened 2G4 antibodies are shown in Table 1 below.
[0241] Table 1
[0242] CDR Sequence SEQ ID NO H-CDR1 GFTFSRYG SEQ ID NO:1 H-CDR2 IWYDGTNK SEQ ID NO:2 H-CDR3 AREDWAEAFD M SEQ ID NO:3 L-CDR1 QSLLHSNGYN Y SEQ ID NO:4 L-CDR2 LGS SEQ ID NO:5 L-CDR3 MQALQTIT SEQ ID NO:6
[0243] The sequences of the heavy chain variable region and light chain variable region of the 2G4 antibody are shown in Table 2:
[0244] Table 2
[0245]
[0246] Preparation Example 2. Preparation of "2G4-SMCC-DM1" (#POC-DM1)
[0247] 2G4-ADC (antibody-drug conjugate) was prepared, which contained SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylate) as a non-cleavable linker and DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine) as a microtubule inhibitor. The linker-paylaod coupling of 2G4 was measured using a UV-Vis spectrophotometer, and the drug-to-antibody ratio (DAR) was determined by liquid chromatography-mass spectrometry (LC-MS) analysis.
[0248] Specifically, 2G4 and human IgG1 (Sino Biological) were dialyzed against coupling buffer (0.1 M sodium phosphate and 0.15 M NaCl, pH 7.2) and coupled to SMCC-DM1 (MedChemExpress) at a molar ratio of 1:5 or 1:10 for 1.5 h at RT. Fractionation was performed to remove unbound SMCC-DM1 and aggregated 2G4-DM1. Antibody fractions were pooled and buffered Granule (10 mM sodium succinate, 0.05% polysorbate 20, The solution was dialyzed with 6% sucrose (pH 5.0). The optical density (OD) at 280 nm and 252 nm was checked using SPECTROstarNano (BMG LABTECH) to determine whether it was coupled. The DAR was determined using liquid chromatography-mass spectrometry (LC-MS) analysis.
[0249] To confirm the coupling of DM1 and 2G4, DM1 absorbs ultraviolet light at 252 nm, so the absorbance of Naked 2G4 and ADC was analyzed at 252 nm using a UV-Vis spectrophotometer, and the absorbance of Naked 2G4 and 2G4-DM1 was compared. The absorbance of 2G4-DM1 at 252 nm was higher than that of 2G4. The results showed that DM1 was potentially coupled to 2G4.
[0250] Mass spectrometry analysis of 2G4-DM1 confirmed that it consisted of various populations ranging from 1 to 4 per antibody drug, with an average DAR of 1.8 for 2G4-DM1.
[0251] Preparation Example 3. Preparation of ADC using a cleavable linker
[0252] Four ADCs were prepared using cleavable linkers. Specifically, the ADCs were conjugated by either classical maleimide conjugation or ADCs were prepared using disulfide rebridging conjugation technology (Abzena, USA) to allow MMAE to bind to SN-38 with an average DAR range of 2 to 8. ADCs with average DARs of 2 and 4 were prepared together with a maleimide MMAE control ADC with an average DAR of 4. MMAE ADC. The average DAR of SN-38 ADC is 8. A cathepsin-cleavable “Val-Cit-PAB” motif is included in all linkers to allow lysosomal release of the payload ( Figure 1a ).for For SN-38 ADC, the carbonate bond connecting SN-38 to the linker is sensitive to hydrolysis, making a pH-based payload release mechanism also possible. Considering subsequent biological testing, ADCs with high monomer purity (>97%) were prepared in quantities of 29-56 mg. The preparation process of -Glu-(Val-Cit-PAB-MMAE)-PEG (24u) is as follows Figure 1b shown.
[0253] Preparation Example 3-1.2 Preparation of G4-MC-VC-PAB-MMAE
[0254] mAb 2G4 was diluted at 13.38 mg / mL in Dulbecco's PBS, pH 7.4, 5 mM EDTA (5.232 mL; 70.0 mg; 470 nmol; 1.0 equiv) with Dulbecco's PBS, pH 7.4, 5 mM EDTA (8.505 mL). A 5 mM solution of tris(2-carboxyethyl)phosphine (TCEP) dissolved in endotoxin-free water (263.4 μL, 1317 nmol, 2.8 equiv) was added to the mAb 2G4 dilution. The reduction was allowed to proceed at 40°C for 2 hours at a final antibody concentration of 5.0 mg / mL.
[0255] After 2 hours at 40°C, the reduction mixture was diluted with Dulbecco's PBS, pH 7.4, 5 mM EDTA (2.450 mL), allowed to cool to 22°C, and then further diluted with DMF (177 μL). 3.95 mg (3.00 μmol) of MC-VC-PAB-MMAE (MW = 1317 g.mol) was added.-1 ) was dissolved in 927 μL of DMF to prepare a 4.26 mg / mL (3.23 mM) solution of MC-VC-PAB-MMAE in DMF. The MC-VC-PAB-MMAE solution in DMF (873 μL; 3.72 mg; 2823 nmol; 6.0 equivalents) was added to the reduced mAb 2G4 solution to a final concentration of 6% DMF and a final antibody concentration of 4.0 mg / mL. The coupling reaction was carried out at 22°C for 1 hour.
[0256] After 1 hour at 22°C, the cells were plated using 20 mM histidine, 50 mM NaCl, 5% sucrose, Zebacore balanced to pH 6.5 according to the manufacturer's instructions. TM The reaction mixture was buffer exchanged by spin filtration using a centrifugal column (Zeba spin Columns) (7 kDa MWCO; 10 mL). The recovered conjugate sample was further ground and concentrated to 7.13 mg / mL by ultrafiltration / diafiltration using a Vivaspin20 centrifugal concentrator (polyethersulfone filter (PES) membrane, 30 kDa MWCO) balanced to pH 6.5. The concentrated conjugate sample (56.3 mg; 7.90 mL) was sterile filtered through a 0.22 μm pore size polyvinylidene fluoride (PVDF) membrane filter.
[0257] The antibody-drug conjugate thus obtained was named "2G4-MC-VC-PAB-MMAE" and characterized by hydrophobic interaction chromatography (HIC) and size exclusion chromatography (SEC). 56 mg of 2G4-MC-VC-PAB-MMAE ADC was isolated with a high monomer content (>98%, SEC) and an average DAR of 4.2 (HIC) (hereinafter referred to as 003-2).
[0258] Preparation Example 3-2.2G4- Preparation of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2
[0259] mAb 2G4 was diluted at 14.77 mg / mL in Dulbecco's PBS, pH 7.4, 5 mM EDTA (2.180 mL; 32.2 mg; 216 nmol; 1.0 equiv) with Dulbecco's PBS, pH 7.4, 5 mM EDTA (4.148 mL). A 5 mM solution of tris(2-carboxyethyl)phosphine (TCEP) in endotoxin-free water (112 μL, 562 nmol, 2.6 equiv) was added to the diluted mAb 2G4 solution. Reduction was allowed to proceed at 40°C for 2 hours at a final antibody concentration of 5.0 mg / mL.
[0260] After 2 hours at 40°C, the reduction mixture was diluted with Dulbecco's PBS, pH 7.4, 5 mM EDTA (805 μL), allowed to cool to 22°C, and further diluted with DMF (403 μL). 2.15 mg (768 nmol) of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)(MW=2805.0g.mol -1 ) was dissolved in 477 μL of DMF to prepare -Glu-(Val-Cit-PAB-MMAE)-PEG (24u) 4.52mg / mL (1.61mM) solution. -Glu-(Val-Cit-PAB-MMAE)-PEG (24u) solution (402 μL; 1.82 mg; 648 nmol; 3.0 equivalents (eq.)) was added to the reduced 2G4 solution to obtain a final concentration of 10% DMF and a final antibody concentration of 4.0 mg / mL. The coupling reaction was carried out at 22°C for 18 hours.
[0261] After 18 hours at 22°C, the cells were plated using 20 mM histidine, 50 mM NaCl, 5% sucrose, Zebacore balanced to pH 6.5 according to the manufacturer's instructions. TMThe reaction mixture was buffer exchanged by spin filtration using a centrifugal column (Zeba spin Columns) (7 kDa MWCO; 10 mL). The recovered conjugate sample was further ground and concentrated to 7.25 mg / mL by ultrafiltration / diafiltration using a Vivaspin20 centrifugal concentrator (polyethersulfone filter (PES) membrane, 30 kDa MWCO) balanced to pH 6.5. The concentrated conjugate sample (29.7 mg; 4.10 mL) was sterile filtered through a 0.22 μm pore size polyvinylidene fluoride (PVDF) membrane filter.
[0262] The antibody-drug conjugate thus obtained was named "2G4- -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 2", and the conjugate was characterized by HIC and SEC. 30 mg of 2G4- -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR2ADC was isolated with high monomer content (>97%, SEC) and an average DAR of 2.0 (HIC) (hereinafter referred to as 003-1).
[0263] Preparation Example 3-3.2G4- Preparation of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4
[0264] mAb 2G4 was diluted at 20.71 mg / mL in Dulbecco's PBS, pH 7.4, 5 mM EDTA (5.794 mL, 120 mg, 806 nmol, 1.0 equiv) with Dulbecco's PBS, pH 7.4, 5 mM EDTA (17 mL). A 5 mM solution of tris(2-carboxyethyl)phosphine (TCEP) dissolved in endotoxin-free water (967.2 μL, 4836 nmol, 6.0 equiv) was added to the mAb 2G4 solution. Reduction was allowed to proceed at 40°C for 1 hour at a final antibody concentration of 5.0 mg / mL.
[0265] After 1 hour at 40°C, the reduction mixture was diluted with propylene glycol (6.40 mL) and cooled to 22°C. -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)(MW=2805.0g.mol -1) 20.60 mg (7345 nmol) was dissolved in 2430 μL of DMF to prepare -Glu-(Val-Cit-PAB-MMAE)-PEG (24u) 8.48 mg / mL (3.02 mM) solution. -Glu-(Val-Cit-PAB-MMAE)-PEG (24u) solution (1600 μL; 13.57 mg; 4836 nmol; 6.0 equiv) was added to the reduced 2G4 solution to give a final concentration of 5% DMF, 20% propylene glycol and a final antibody concentration of 3.8 mg / mL. The coupling reaction was carried out at 22°C for 18 hours.
[0266] After 18 hours at 22°C, the reaction mixture was diluted with 4M sodium chloride, 50mM sodium phosphate pH 7.0 (32.0 mL). The diluted reaction mixture was loaded onto a Proteus FliQ 10 mL column packed with HIC equilibrated with buffer A (2.0M sodium chloride, 50mM sodium phosphate, pH 7.0 buffer). Phenyl-650S resin. Elution was performed in buffer B (50 mM sodium phosphate, 20% isopropanol, pH 7.0) with a conjugate constant flow of 1.5 mL / min and a 200 mL gradient of 0-100%. Fractions were analyzed by HIC and SEC and combined according to the 4 DAR contents (>90%). The combined fractions were buffer exchanged and concentrated to 7.93 mg / mL by ultrafiltration / diafiltration using a Vivaspin 20 centrifugal concentrator (polyethersulfone filter (PES) membrane, 30 kDa MWCO) balanced to pH 6.5. The concentrated conjugate sample (47.4 mg; 5.98 mL) was sterile filtered through a polyvinylidene fluoride (PVDF) membrane filter with a pore size of 0.22 μm.
[0267] The antibody-drug conjugate thus obtained was named "2G4- -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4 conjugate", and the conjugate was characterized by HIC and SEC. 47 mg of 2G4- -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)DAR4 ADC was isolated with high monomer content (>98%, SEC) and an average DAR of 4.0 (HIC) (hereinafter referred to as 004-2).
[0268] Preparation Example 3-4.2G4- Preparation of -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2
[0269] mAb 2G4 was diluted at 18.71 mg / mL in Dulbecco's PBS, pH 7.4, 5 mM EDTA (3.474 mL, 65.0 mg, 437 nmol, 1.0 equiv) with Dulbecco's PBS, pH 7.4, 5 mM EDTA (9.00 mL). 5 mM tris(2-carboxyethyl)phosphine (TCEP) dissolved in endotoxin-free water (524.0 μL; 2620 nmol, 6.0 equiv) was added to the diluted mAb 2G4 solution. Reduction was allowed to proceed at 40°C for 1 hour at a final antibody concentration of 5.0 mg / mL.
[0270] After 1 hour at 40°C, the reduction mixture was diluted with propylene glycol (3.71 mL) and cooled to 22°C, then further diluted with DMF (655 μL). 14.09 mg (3072 nmol) of -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2(MW=4588.0g.mol -1 ) was dissolved in 1409 μL of DMF to prepare -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2 10.0 mg / mL (2.18 mM) solution. DMF solution (1202 μL; 12.02 mg; 2620 nmol; 6.0 equivalents) was added to -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2 was added to the reduced 2G4 solution to yield a final concentration of 10% DMF, 20% propylene glycol and a final antibody concentration of 3.5 mg / mL. The coupling reaction was carried out at 22°C for 18 hours.
[0271] After 18 hours at 22°C, the reaction mixture was diluted with 4 M sodium chloride, 50 mM sodium phosphate, pH 7.0 (18.6 mL). The diluted reaction mixture was loaded onto a Proteus FliQ 10 mL column packed with HIC equilibrated with buffer A (2.0 M sodium chloride, 50 mM sodium phosphate, pH 7.0 buffer). Phenyl-650S resin. Elution was performed in buffer B (50 mM sodium phosphate, 20% isopropanol, pH 7.0) with a conjugate constant flow of 1.5 mL / min and a 200 mL gradient of 0-100%. Fractions were analyzed by HIC and SEC and combined according to the 4 DAR contents (>80%). The combined fractions were buffer exchanged by ultrafiltration / diafiltration and concentrated to 4.01 mg / mL using a Vivaspin 20 centrifugal concentrator (polyethersulfone filter (PES) membrane, 30 kDa MWCO) balanced to pH 6.5 with 20 mM histidine, 50 mM NaCl, 5% sucrose. The concentrated conjugate sample (29.0 mg; 7.22 mL) was sterile filtered through a 0.22 μm pore size polyvinylidene fluoride (PVDF) membrane filter.
[0272] The antibody-drug conjugate thus obtained was named "2G4- -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2 conjugate", and the conjugate was characterized by LC-MS and SEC. 29 mg of 2G4- -Glu-[(Val-Cit-PAB-SN-38)]2-Glu-[PEG(24u)]2 was separated with high monomer content (>98%, SEC) and an average DAR of 7.4 (LC-MS) (hereinafter referred to as 007-1).
[0273] Analytical methods
[0274] (1) Liquid chromatography-mass spectrometry (LC-MS) analysis
[0275] LC-MS analysis was performed using a POROSHELL 300SB C3 column (2.1×12.5 mm, 5 μm) connected to a Waters XEVO G2S TOF mass spectrometer and a Waters Acquity H Class UPLC system. The mobile phase was buffer A (0.1% formic acid in water). A gradient (10% B for 2.5 minutes, 10-80% B gradient for 3.5 minutes) was applied using buffer B (acetonitrile, 0.1% formic acid). The column was maintained at 60°C throughout the analysis. Maleimide ADCs were analyzed after reduction (10 mM DTT, 40°C for 1 hour). All ADCs were diluted to 0.2 mg / mL. 10 μL of ADC solution was injected for analysis. The average DAR was calculated by the weighted average of the DAR species observed based on the major glycoform signal intensity (SI) of the deconvoluted m / z spectra of the non-reduced sample and the signal intensities of the light chain (LSI) and heavy chain (HSI) of the reduced sample:
[0276]
[0277] (2) Size Exclusion Chromatography (SEC) Analysis
[0278] The HPLC-MS / MS was carried out using an ACQUITY UPLC BEH SEC column (4.6 mm × 15 cm, SEC analysis was performed using a 400 μm column (1.7 μm) and a guard column (4.6 mm × 3 cm). The mobile phase was 0.2 M potassium phosphate buffer, pH 6.8, 0.2 M potassium chloride, 15% (v / v) isopropanol. The flow rate was kept constant at 0.35 mL / min. The column was kept at 30°C throughout the analysis. Analysis was performed by UV detection at 248 nm, 280 nm, and 365 nm with a 10-minute isocratic elution. 10 μg of ADC was injected for analysis. The percentage of high molecular weight (HMW) species was calculated by comparing the peak area corresponding to the HWM species at 280 nm with the total peak area corresponding to the HWM and monomer species at 280 nm. The presence of free reagent-related species was evaluated by comparing the chromatograph traces of the ADC and buffer samples at the wavelength corresponding to the maximum absorbance of the payload (λ = 248 nm for monomethyl auristatin E (MMAE) and λ = 365 nm for SN-38) in the low molecular weight species region of the chromatogram with retention times exceeding 6 minutes.
[0279] (3) Hydrophobic interaction chromatography (HIC) analysis
[0280] HIC analysis was performed using a TOSOH Bioscience TSKgelButyl-NPR column (4.6 mm × 3.5 cm, 2.5 μm) connected to a Dionex Ultimate 3000UPLC system. The mobile phase was buffer A: 1.5 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0. To elute the bound species, a linear gradient (0-100% B in 10.5 minutes) was applied using buffer B (20% isopropanol, 50 mM sodium phosphate, pH 7.0) at a flow rate of 1.35 mL / min. The column was maintained at °C throughout the analysis. Analysis was performed by UV detection at 280 nm. 10 μg of ADC was injected for each analysis. The percentage of each DAR species (i) was calculated by comparing the peak area of each assigned peak to the total peak area. The average DAR was calculated by the weighted average of the DAR species observed based on the peak area under the curve (AUCi), and the average molecular weight of the ADC was calculated based on the DAR and linker-payload mass contribution as follows:
[0281]
[0282] MW ADC =MW mAb +DAR×MW LP
[0283] Example
[0284] Example 1. In vitro cell viability analysis
[0285] To confirm the efficacy of the ADCs presented in Table 3 in c-Kit-positive and negative cancer cell lines, in vitro cell viability assays were performed.
[0286] Cells were seeded in 96-well cell culture black plates (Greiner Bio-One, Kremsmuenster, Austria) and the number of cells was scanned using a Celigo Imaging Cytometer device. Nine concentration points of the ADC were prepared by serial dilutions of 5 or 10 times at a starting concentration of 40 μg / ml or 200 μg / ml. After 3-5 days of treatment, cells were stained with Calcein-AM (1 μg / ml) or Hoechst 33342 (8 μM) fluorescent dyes. For cell counting, wells were scanned and analyzed using a Celigo Imaging Cytometer. Cell viability was plotted using Graph PadPrism Software to calculate half-maximal inhibitory concentration (IC50) values (Table 4).
[0287] Table 3
[0288]
[0289] Table 4
[0290]
[0291] like Figure 2 As shown, it can be seen that the ADC group showed statistically significant efficacy compared with the control group.
[0292] Example 2. In vivo efficacy of mice (GIST T1 cells) against gastrointestinal stromal tumors (GIST)
[0293] The experiment was conducted to evaluate the efficacy of ADC substances against GIST using a GIST-T1 cell (c-Kit mutant and imatinib sensitivity; commission number: CVCL_4976; c-Kit mutation site-Exon11 V560-L576) xenograft model.
[0294] Four-week-old female CB-17SCID immunodeficient mice (Charles River Laboratories Japan, Inc.) were used for the experiment after being kept in a specific pathogen free (SPF) environment for 12 days. GIST-T1 cells (5×10 6 / 100 μL / head / serum-free, Dulbecco's modified Eagle's medium / high glucose medium (5×10 6 / 100μL / Head / Serum free, DMEM / High glucose medium)). The total injection volume containing suspended cells is 200μL.
[0295] On day 21 after transplantation, the average tumor volume was approximately 190 mm 3Mice were registered as Day 0. After random assignment to one of 6 groups (n=5 / group), mice were administered ADC vehicle (5 ml / kg, ivtail), each ADC substance (0.5, 1.5 or 3.0 mg / kg, intravenous injection (iv) tail), imatinib (100 mg / kg, oral (po)) and ADC substance (3.0 mg / kg, intravenous injection (iv) tail) + imatinib (100 mg / kg, oral (po)) (Table 5). As ADC carriers, the buffer for PoC-DM1 was a mixture of 10 mM sodium succinate, 6% sucrose and 0.05% Tween-20 (Tween 20) (pH 5.0), and the buffers for the rest were 20 mM histidine (Merck, 104352), 50 mM sodium chloride (Sigma, S3014), 5% sucrose (Sigma, S0389) (PH 6.5) and 0.22 μM filter (Merck, S2GPU11RE) Individual doses were given in a dose volume of 5 mL / kg body weight based on the animal weight recorded prior to dosing. For the base Accurately calculated.
[0296] Table 5
[0297]
[0298] The ADC substances administered are shown in Table 6:
[0299] Table 6
[0300]
[0301] All animals were observed once a day for mortality, general status, and clinical manifestations (time, onset, severity, and recovery). Tumor volume and body weight were measured twice a week. To determine tumor volume, length, width, and depth were measured using calipers.
[0302] The results are shown in Figure 3a to Figure 3d .
[0303] During the pre-sacrifice test, no abnormal symptoms were observed in all groups except the imatinib 100 mg / kg group. One death occurred on Day 91 in the imatinib 100 mg / kg group.
[0304] Compared with the control group (vehicle), no more than 10% weight loss or weight gain was observed in the imatinib 100 mg / kg group and the test ADC study group (0.5 mg / kg, 1.5 mg / kg, 3.0 mg / kg, 3.0 mg / kg + imatinib 100 mg / kg) within 56 days. Thereafter, no rapid weight loss or rapid weight gain was observed in any group. This shows that the inventor's ADC substances are very safe.
[0305] On day 56, imatinib 100 mg / kg group inhibited tumor growth compared with the control group (vehicle), whereas 3.0 mg / kg of all ADC study groups showed stronger tumor growth inhibition effects. The ADC study group of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u) (#003-1 and #004-2) showed significant tumor growth inhibition effect even at 1.5 mg / kg.
[0306] Although imatinib alone suppressed the tumors, they recurred after cessation of treatment. Surprisingly, combination therapy with imatinib at 3 mg / kg per ADC induced complete tumor remission with no regrowth until 105 or 112 days after cessation of imatinib administration.
[0307] After sacrifice, tumor weighing results showed that compared with the control group (vehicle), imatinib 100 mg / kg administration The group with 1.5 mg / kg or more of ADC (except for the group with 1.5 mg / kg of PoC-DM1) showed a higher ability to decrease (Table 7). The ADC study group of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u) (#003-1 and #004-2) showed significant tumor growth inhibition efficacy even in the 1.5 mg / kg group. When each 3 mg / kg ADC was administered in combination with imatinib, most of the tumors disappeared.
[0308] Table 7
[0309]
[0310] The above results support that the ADC group has statistically significant efficacy compared with the control group.
[0311] Example 3: In vivo efficacy against GIST in mice (GIST-430 / 654 cells)
[0312] In particular, the efficacy of ADC substances against imatinib-resistant GIST was also evaluated. A GIST-430 / 654 cell (imatinib-resistant, Exon 11V560-L576+Exon 13V654A) xenograft model was used.
[0313] Five-week-old female NOG (NOD / Shi-scid, IL-2RγKO) immunodeficient mice (CIEA Japan, Inc.) were acclimated for 12 days under specific pathogen free (SPF) conditions before use in the experiment. Six-week-old mice were subcutaneously injected with GIST-430 / 654 cells (5×10 6 / 100μL / Head / Serum free, IMDM medium). The total injection volume containing suspended cells is 200μL.
[0314] On day 21 after transplantation, mice were enrolled in this study and the average tumor volume was approximately 180 mm 3 (Day 0). After random assignment to one of five groups (n=5 / group), mice were administered ADC vehicle (5 ml / kg, ivtail), each ADC substance (1, 3 or 5 mg / kg, intravenous (iv) tail) and imatinib (100 mg / kg, oral (po)) (Table 8). As ADC vehicle, the buffer for PoC-DM1 was a mixture of 10 mM sodium succinate, 6% sucrose and 0.05% Tween-20 (Tween20) (pH5.0), and the buffer for the rest was a mixture of 20 mM histidine (Merck, 104352), 50 mM NaCl (Sigma, S3014), 5% sucrose (Sigma, S0389) (pH6.5) and 0.22 μM filter (Merck, S2GPU11RE). Individual doses were calculated using a dose volume of 5 mL / kg body weight based on the animal weight recorded before dosing.
[0315] Table 8
[0316] No. Subject Interval, Route 1 Control(vehicle,ADC buffer) D0, D7, D14 (three times), intravenous injection (iv) 2 Imatinib 100mg / kg D0-D29 (daily for 30 days), oral (po) 3 ADC1mg / kg D0, D7, D14 (three times), intravenous injection (iv) 4 ADC3mg / kg D0, D7, D14 (three times), intravenous injection (iv) 5 ADC5mg / kg D0, D7, D14 (three times), intravenous injection (iv)
[0317] The ADC substances are shown in Table 9 below:
[0318] Table 9
[0319]
[0320] The dates of sacrifice for each group are as follows:
[0321] - Vehicle and imatinib 100 mg / kg: sacrificed on day 49.
[0322] - All ADC groups (except 007-1): sacrificed on day 63.
[0323] - Group #007-1: sacrificed on day 42 (Group #007-1 was terminated earlier than the control group (vehicle), so no comparison was made).
[0324] All animals were observed once a day for mortality, general status, and clinical manifestations (time, onset, severity, and recovery). Tumor volume and body weight were measured twice a week. To determine tumor volume, length, width, and depth were measured using calipers.
[0325] The results are shown in Figures 4a to 4e .
[0326] During the experimental period before sacrifice, no abnormal symptoms were observed in all groups.
[0327] Between the imatinib 100 mg / kg group and the test ADC study groups (1 mg / kg, 3 mg / kg and 5 mg / kg), no more than 10% weight loss or body weight was observed over 49 days compared to the control group (vehicle). Subsequently, no rapid weight loss or rapid weight gain was observed in any group. This indicates that the ADC substances of the present invention are all safe.
[0328] On day 49, compared with the control group (vehicle), the imatinib 100 mg / kg group had almost no inhibitory effect on tumor growth, whereas the ADC study groups all showed stronger tumor growth inhibition effects (except for #007-1 1 mg / kg). The ADC study group of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)(#003-1 and #004-2) at 3 or 5 mg / kg had a significant inhibitory effect on tumor growth, and after stopping treatment, the tumor remained at almost the same level.
[0329] After sacrifice, tumor weights were weighed and all study groups (except #007-1; terminated earlier than the control group) showed a higher decrease compared to the control group (vehicle) (see Table 10 below). The ADC study group of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)(#003-1 and #004-2) showed significant tumor growth inhibition effect.
[0330] Table 10
[0331] (reduction%) #PoC-DM1 #003-1 #004-2 #003-2 3mg / kg 23.9 49.1 78.0 34.2 5mg / kg 17.6 67.3 87.4 70.2
[0332] The above results support that the ADC group has statistically significant efficacy compared with the control group.
[0333] Example 4: In vivo efficacy against SCLC in mice (SCLC-H526 cells)
[0334] Experiments were conducted to evaluate the efficacy of ADC substances on SCLC. SCLC-H526 (NCI-H526, stage E, carcinogenesis; variant small cell lung cancer, c-Kit overexpression) xenograft model was used.
[0335] In addition to using 50% Matrigel (Corning, 354248, NY, USA) for SCLC-H526 cells (2×10 6 / 100 μL / Head / Serum free, RPMI-1640 medium), the analysis was performed in the same manner as in Example 2. On day 13 after transplantation, mice were enrolled in the study, and the average tumor volume was about 165 mm 3 (Day 0); oral administration for 22 days from D0 to D21. The study groups were #PoC-DM1, #003-1, #004-2 and #003-2.
[0336] The above is shown in Figure 5a to Figure 5d .
[0337] Before sacrifice, no abnormal symptoms were observed in the whole group during the experiment.
[0338] Between the imatinib 100 mg / kg group and the test ADC study groups (1 mg / kg, 3 mg / kg and 5 mg / kg), no more than 10% weight loss or weight gain was observed over 21 days compared to the control group (vehicle). In addition, no rapid weight loss or rapid weight gain was observed in any group. This indicates that the ADC substances of the present invention are very safe.
[0339] On day 21, the imatinib 100 mg / kg group barely inhibited tumor growth compared to the control group (vehicle), whereas the ADC study groups at 3 or 5 mg / kg showed stronger tumor growth inhibition effects (except for #007-1 1 mg / kg). In particular, surprisingly, treatment with the #004-2 3 mg / kg group and the #004-2 5 mg / kg group induced complete tumor remission, with no regrowth even after stopping dosing for up to 105 days.
[0340] After sacrifice, tumor weights were weighed and all study groups (except #007-1; terminated earlier than the control group) showed a higher reduction compared to the control group (vehicle) (see Table 11 below). The ADC study group of -Glu-(Val-Cit-PAB-MMAE)-PEG(24u)(#004-2) showed significant tumor growth inhibition effect.
[0341] Table 11
[0342] (reduction%) #PoC-DM1 #003-1 #004-2 #003-2 5mg / kg 73.8 60.0 99.5 53.7
[0343] The above results support that the ADC group has statistically significant efficacy compared with the control group.
[0344] Example 5: In vivo efficacy against mastocytoma in mice (HMC 1.2 cells)
[0345] Experiments were conducted to evaluate the efficacy of NN3201 (2G4- -Glu(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4; #004-2). HMC 1.2 (c-Kit mutation and imatinib resistance; Exon11(V560G)+Exon17(D816V)) xenograft model was used.
[0346] Four-week-old female CB-17SCID immunodeficient mice (Janvier France, Inc.) were acclimated for 18 days under specific pathogen free (SPF) conditions for use in the experiment. Six-week-old mice were subcutaneously injected with HMC-1.2 cells (1×10 6 / 100μL / Head / Serum free, IMDMmedium). The total injection volume containing suspended cells is 200μL.
[0347] On day 11 after transplantation, mice were enrolled in the study and the average tumor volume was approximately 175.4 mm 3 (Day 0). After random assignment to each group (n=6 / group), mice were administered ADC vehicle (5 ml / kg, ivtail), 2G4 (5 mg / kg, ivtail), #PoC-DM1 (5 mg / kg, ivtail), NN3201 (1, 3 or 5 mg / kg, ivtail) and imatinib (100 mg / kg, po). The ADC vehicle used a mixture of 20 mM histidine (Merck, 104352), 50 mM NaCl (Sigma, S3014), 5% sucrose (Sigma, S0389) (pH 6.5) and 0.22 μM filter (Merck, S2GPU11RE). Individual doses were calculated using a dose volume of 5 mL / kg body weight based on the animal weight recorded before administration. Intravenous (iv) injections were performed in three batches on D0, D7, and D14, and imatinib was administered orally for 18 days from D0 to D17.
[0348] The results are shown in Figure 6 .
[0349] No abnormal symptoms were observed in all groups during the trial.
[0350] In 17 days, no more than 10% weight loss or weight gain was observed between the imatinib 100 mg / kg group and the test group compared to the control group (vehicle). Subsequently, no rapid weight loss or rapid weight gain was observed in any group. This indicates that the ADC substance of the present invention is very safe.
[0351] On the 17th day, the imatinib 100 mg / kg group could hardly inhibit the tumor. On the contrary, the ADC study group showed a stronger tumor proliferation inhibition effect compared with the control group (vector).
[0352] Tumors were re-inoculated on day 77. On day 95, compared with the control group (first-) inoculation group, TGI (tumor growth inhibition) was 71.0% in the #NN3201 1 mg / kg (re-) inoculation group, 79.0% in the #NN3201 3 mg / kg (re-) inoculation group, and 74.8% in the #NN3201 5 mg / kg (re-) inoculation group. In addition, the #PoC-DM1 5 mg / kg (re-) inoculation group showed a tumor inhibition of 46.2% ( Figure 7 ).
[0353] The above results support that the ADC group has statistically significant efficacy compared with the control group.
[0354] Example 6: In vivo efficacy against AML in mice (Kasumi-1 cells)
[0355] This study was conducted to evaluate the efficacy of NN3201 (2G4 -Glu(Val-Cit-PAB-MMAE)-PEG(24u)DAR 4) was used as a xenograft model of Kasumi-1 (c-Kit mutation and partial imatinib sensitivity; Exon17(N822K)).
[0356] In addition to using 50% Matrigel (Corning, 354248, NY, USA), Kasumi-1 cells (3 × 10 6 The experiment was carried out in the same manner as in Example 5 except that the cells were treated with 100 μL / Head / Serum free, RPMI1640 medium. On day 29 after transplantation, the mice were enrolled for study, and the average tumor volume was about 170 mm 3 (Day 0).
[0357] The results are shown in Figure 8 .
[0358] No abnormal symptoms were observed in all groups during the trial.
[0359] In 17 days, no weight loss or weight gain of more than 10% was observed between the imatinib 100 mg / kg group and the test group compared with the control group (vehicle). Subsequently, no rapid weight loss or rapid weight gain was observed in any group. This indicates that the ADC substances of the present invention are very safe.
[0360] On day 17, compared with the control group (vehicle), the imatinib 100 mg / kg group had almost no inhibition of tumor growth, and the PoC-DM1 group showed a weak inhibitory effect. It was also confirmed that the NN3201 group had a stronger tumor growth inhibitory effect.
[0361] The above results support that the ADC group has statistically significant efficacy compared with the control group.
[0362] Example 7: In vivo efficacy against breast cancer in mice (MDA-MB-468 cells)
[0363] Experiments were performed to evaluate the efficacy of ADC substances against breast cancer. The MDA-MB-468 (c-Kit, Negative) xenograft model was used in this experiment.
[0364] In addition to using 50% Matrigel (Corning, 354248, NY, USA), MDA-MB-468 cells (5×10 6 The experiment was performed in the same manner as in Example 5 except that the cells were lysed in 100 μL / Head / Serum free, DMEM medium. On day 21 after transplantation, the mice were enrolled in the study, and the average tumor volume was approximately 167 mm 3 (Day0).
[0365] The results are shown in Figures 9a to 9d .
[0366] During the experimental period before sacrifice, no abnormal symptoms were observed in all groups.
[0367] Compared to the control group (vehicle), no more than 10% weight loss or weight gain was observed between the imatinib 100 mg / kg group and the test ADC study groups (1 mg / kg, 3 mg / kg and 5 mg / kg) within 49 days. Subsequently, no rapid weight loss or rapid weight gain was observed in any group. This indicates that the ADC substances of the present invention are very safe.
[0368] On day 49, #PoC-DM1 showed no antitumor activity in heterologous transplants with MDA-MB-468 cells lacking c-Kit expression compared to the control group (vehicle); whereas #003-1, #004-2, and #003-2 had stronger tumor growth inhibition effects at all doses. In particular, it was confirmed that the group treated with 5 mg / kg of #004-2 significantly inhibited tumor growth.
[0369] After sacrifice, the tumors were weighed and the results showed that compared with the control group (vehicle), #003-1, #004-2, and #003-2 showed a reduction in tumors (see Table 12 below). In particular, the #004-2 group had a significant tumor growth inhibition effect.
[0370] Table 12
[0371] (reduction%) #003-1 #004-2 #003-2 5mg / kg 41.2 84.6 62.0
[0372] Interestingly, the MDA-MB-468 results showed that the ADC using 2G4, a cleavable linker, and MMAE showed dose-dependent efficacy in a xenograft model based on c-Kit negative cells, whereas the ADC using a non-cleavable linker did not. This result suggests that the ADC including 2G4, a cleavable linker, and MMAE can also be an ideal partner in the case of non-targeting c-Kit.
[0373] Example 8: In vivo efficacy against SCLC in mice (SCLC-H526 cells) - re-challenge analysis Tumor re-challenge analysis was performed to determine whether NN3201 treatment was also effective after re-inoculation of tumors.
[0374] The analysis was performed in the same manner as in Example 3, except that the experimental groups were the #004-2 group at 3 mg / kg and 5 mg / kg alone. Tumor re-challenge was performed at the time of complete tumor remission (day 63). The control cohort (squares) used animals of the same age as the control group that received the first tumor inoculation on day 63, without the initial tumor implantation on the right side. For xenograft analysis, SCLC-H526 (2×10 6 / 100 μL / Head / Serumfree, RPMI-1640 medium) cells were injected sc (subcutaneously, left flank) into CB-17 SCID mice.
[0375] The results are shown in Fig.10 .
[0376] In tumor re-challenge, the 3 mg / kg and 5 mg / kg #004-2 groups showed dose-dependent efficacy without further ADC injection, whereas the control group resulted in tumor growth.
[0377] Example 9: In vivo efficacy against mastocytoma in mice (HMC 1.2 cells) - re-challenge analysis
[0378] Tumor re-challenge analysis was performed to confirm whether NN3201 treatment was also effective after re-inoculation of tumors.
[0379] The time of complete tumor remission confirmed in Example 4 (day 77), tumor re-challenge analysis was performed in the NN3201 (1, 3 or 5 mg / kg, ivtail) group. The inventors included PoC DM1 ADC to understand the difference between DM1 and MMAE from the perspective of immunogenic cell death (ICD) with payload. Animals of the same age were used as a control group. For xenograft analysis, HMC-1.2 cells (1×10 6 / 100 μL / Head / Serum free, IMDM medium) cells were injected sc (subcutaneously, left flank) into CB-17 SCID mice.
[0380] The results are shown in Fig.11 .
[0381] In the tumor re-challenge analysis, the NN3201 group showed dose-dependent efficacy without further ADC injection, whereas the control group resulted in tumor growth. The PoC-DM1 group showed lower tumor growth inhibition compared with NN3201, and NN3201 showed a stronger effect than PoC-DM1.
[0382] Example 10: Preliminary analysis of in vivo toxicity (10 mg / kg)
[0383] Experiments were conducted to examine changes in body weight over 2 weeks and to evaluate the toxicity of ADC substances when administered as a single iv dose at a high concentration to Balb / c mice.
[0384] 7-week-old female BALB / c mice (Dahan Biochain) were acclimated under specific pathogen free (SPF) conditions before being used in the experiment. After being randomly assigned to one of the 6 groups (n=3 / group), the mice were administered with ADC carrier (5 ml / kg, ivtail) and each ADC substance (10 mg / kg, ivtail). As the ADC carrier, the buffer was a mixture of 20 mM histidine (Merck, 104352), 50 mM NaCl (Sigma, S3014), 5% sucrose (Sigma, S0389) (pH 6.5) and 0.22 μM filter (Merck, S2GPU11RE). The individual dose was calculated based on the animal weight recorded before administration at a dose volume of 5 mL / kg body weight (Table 13).
[0385] Table 13
[0386]
[0387] The mortality rate, general condition and clinical manifestations (time, onset, severity and recovery) of all animals were observed once a day. All animals were weighed every day starting from the grouping date. The animals were sacrificed on the 14th day.
[0388] After the experiment, the animals were euthanized (pulmonary congestion may be affected when using respiratory anesthetics or CO2 chamber euthanasia, so to minimize pain, cervical dislocation was performed as soon as possible) and autopsied to confirm the presence of signs of pulmonary congestion. Tissues (lungs) were stored in 10% NBF (neutral buffered formalin).
[0389] The results are shown in Fig.12 middle.
[0390] No abnormal symptoms were observed in all groups during the trial.
[0391] During the test period, no symptoms of abnormal body weight (more than 5%), such as rapid weight loss or rapid weight gain in response to drug administration, were observed in any group.
[0392] At the end of the experiment (Day 14), the body weight increased by 0.43 g (2.10%) in the #003-1 10 mg / kg group and by 0.63 g (3.00%) in the #004-2 10 mg / kg group compared to the day of administration (Day 0). The body weight of the #003-2 10 mg / kg administration group at the end of the experiment (Day 14) decreased by 0.27 g (1.29%) compared to the day of administration (Day 0).
[0393] There was no pulmonary congestion in the lung tissues of all groups.
[0394] Example 11: In vivo preliminary toxicity analysis (20 / 40 / 60 mg / kg)
[0395] Experiments were conducted to examine changes in body weight over 2 weeks and to evaluate the toxicity of ADC substances when a single iv administration at a high concentration was performed to Balb / c mice.
[0396] The analysis was performed in the same manner as in Example 10 except that the groups were arranged as follows (Table 14).
[0397] Table 14
[0398]
[0399] The results are shown in Figures 13a to 13d middle.
[0400] No abnormal symptoms were observed in the whole group during the trial.
[0401] During the test, no abnormal weight (more than 5%) symptoms such as rapid weight loss or rapid weight gain were observed in each group. On the first day after administration (Day 0), a weight loss of 0.63 g (3.23%) was observed in the #PoC-DM1 40 mg / kg group, and a weight loss of 0.70 g (3.57%) was observed in the #PoC-DM1 60 mg / kg group. However, the lost weight was recovered.
[0402] The above describes the embodiments of the present invention. However, any person skilled in the art can make various modifications and changes to the present invention by adding, changing, deleting or adding constituent elements without departing from the scope of the invention as described in the scope of protection of the invention. This should also be included in the scope of protection of the invention.
Claims
1. An antibody-drug conjugate, characterized in that: It is represented by the following formula 1: Ab-(L) x -(D) y Formula 1 In the formula, Ab is an anti-c-Kit antibody or an antigen-binding fragment thereof that specifically binds to an epitope of human c-Kit in SEQ ID NO: 9 or SEQ ID NO: 10; L is a linker comprising a cleavable linker; D is the drug part; x is an integer from 1 to 8; y is an integer from 1 to 8.
2. The antibody-drug conjugate according to claim 1, characterized in that The Ab is an antibody or an antigen-binding fragment thereof that specifically binds to one or more of R122, Y125, R181, K203, R205, S261 and H263 in sequence number 12.
3. The antibody-drug conjugate according to claim 1, characterized in that: The antibody or its antigen-binding fragment competes with a control antibody comprising heavy chain CDR1 of sequence number 1, heavy chain CDR2 of sequence number 2, heavy chain CDR3 of sequence number 3, light chain CDR1 of sequence number 4, light chain CDR2 of sequence number 5 and light chain CDR3 of sequence number 6 for binding to the epitope of human c-Kit at sequence numbers 9 and 10.
4. The antibody-drug conjugate according to claim 1, characterized in that: The antibody or its antigen-binding fragment comprises the heavy chain CDR1 of sequence number 1, the heavy chain CDR2 of sequence number 2, the heavy chain CDR3 of sequence number 3, the light chain CDR1 of sequence number 4, the light chain CDR2 of sequence number 5 and the light chain CDR3 of sequence number 6.
5. The antibody-drug conjugate according to claim 1, characterized in that: The antibody or antigen-binding fragment thereof comprises a heavy chain variable domain represented by sequence number 7 and a light chain variable domain represented by sequence number 8.
6. The antibody-drug conjugate according to claim 3 or 5, characterized in that: The antibody or antigen-binding fragment thereof is a fragment in which one or two amino acids in the CDR are modified, deleted or substituted.
7. The antibody-drug conjugate according to any one of claims 1 to 6, characterized in that: The antibodies or antigen-binding fragments thereof retain 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more of their identity within the heavy chain variable or light chain heavy chain domain.
8. The antibody-drug conjugate according to claim 1, characterized in that: The L is a linker including a spacer in a form of being linked to a polymer or not linked to a polymer.
9. The antibody-drug conjugate according to claim 1, characterized in that: The linker L has the structure of the following formula 2: (L1) m -(S) n -(L2) p Formula 2 In the formula, L1 is a linker connecting the Ab and S or connecting Ab and L2; S is a spacer in a form that is either linked to a polymer or not linked to a polymer; L2 is a cleavable linker; m is an integer from 0 to 8; n is an integer from 0 to 8; p is an integer from 1 to 8.
10. The antibody-drug conjugate according to claim 9, characterized in that: The m is 1 to 4, the n is 1 to 4, and the p is 1 to 4.
11. The antibody-drug conjugate according to claim 9, characterized in that: The L1 comprises a linker selected from the group consisting of a cleavable linker, a non-cleavable linker, a hydrophilic linker, a pre-charged linker and a dicarboxylic acid-based linker.
12. The antibody-drug conjugate according to claim 1 or 9, characterized in that: The L or L1 includes 13. The antibody-drug conjugate according to claim 9, characterized in that: The S includes a selection of as well as The spacer in the group consisting of.
14. The antibody-drug conjugate according to claim 9, characterized in that: The S is a spacer including aspartic acid, glutamic acid, or a combination thereof in a form in which the polymer is linked or not linked.
15. The antibody-drug conjugate according to claim 9, characterized in that: The polymer is a polyalkylene, a polyalkylene glycol, a polyvinyl pyrrolidone, a polyacrylate, a polyoxazoline, a polyvinyl alcohol, a polyacrylamide or a polymethacrylamide, a hydroxypropyl methacrylate copolymer, a polyester, a polyoxymethylene, a polyorthoester, a polycarbonate, a poly(iminocarbonate), a polyamide, a copolymer of divinyl ether-maleic anhydride or styrene-maleic anhydride, a polysaccharide, or a polyglutamic acid.
16. The antibody-drug conjugate according to claim 9, characterized in that: The L2 includes a linker selected from the group consisting of valine-citrulline-p-aminobenzylcarbamoyl Val-Cit-PAB, alanine-phenylalanine-p-aminobenzylcarbamoyl Ala-Phe-PAB, alanine-alanine-p-aminobenzylcarbamoyl Ala-Ala-PAB, valine-alanine-p-aminobenzylcarbamoyl Val-Ala-PAB, phenylalanine-lysine-p-aminobenzylcarbamoyl Phe-Lys-PAB, alanine-alanine-glycine-p-aminobenzylcarbamoyl Ala-Ala-Gly-PAB and glycine-glycine-p-aminobenzylcarbamoyl Gly-Gly-Gly-PAB linkers.
17. The antibody-drug conjugate according to claim 1, characterized in that: The linker L comprises a linker selected from the group consisting of the following formulae 3 to 5:
18. The antibody-drug conjugate according to claim 1, characterized in that: The drug portion D is selected from the group consisting of V-ATPase inhibitors, apoptosis promoters, Bcl2 inhibitors, MCL1 inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule inhibitors, auristatins, dolastatins, maytansinoids, MetAP methionine aminopeptidase, inhibitors of nuclear export of protein CRM1, DPPIV inhibitors, proteasome inhibitors, inhibitors of phosphotransfer reactions in mitochondria, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, kinesin inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalators, DNA minor groove binders and DHFR inhibitors.
19. The antibody-drug conjugate according to claim 18, characterized in that: The drug moiety D is a microtubule inhibitor moiety.
20. The antibody-drug conjugate according to claim 19, characterized in that The drug portion D includes a drug selected from the group consisting of SN-38 ((4S)-4,11-diethyl-4,9-dihydroxy-1,4-dihydro-3H,14H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14-dione), auristatin, dolastatin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), monomethyl dolastatin 10 (MMAD), or a combination thereof.
21. The antibody-drug conjugate according to claim 1, characterized in that: The antibody-drug conjugate is selected from the group consisting of the following formulas 6 to 8: In the above formula, a is an integer of 1 to 8, and b and c are integers of 1 to 4, respectively.
22. An antibody-drug conjugate, characterized in that Selected from the group consisting of the following formulae 6 to 8: In the formula, Ab is an antibody or an antigen-binding fragment thereof comprising the heavy chain CDR1 of sequence number 1, the heavy chain CDR2 of sequence number 2, the heavy chain CDR3 of sequence number 3, the light chain CDR1 of sequence number 4, the light chain CDR2 of sequence number 5, and the light chain CDR3 of sequence number 6; a is an integer of 1 to 8, and b and c are integers of 1 to 4, respectively.
23. A pharmaceutical composition for cancer prevention or treatment, characterized in that: Comprising the antibody-drug conjugate of claim 1 or 22.
24. A method for preventing or treating cancer, characterized in that: The method comprises the step of administering a pharmaceutically effective amount of a composition comprising the antibody-drug conjugate of claim 1 or 22 to a subject in need of the composition.
25. A therapeutic use of the antibody-drug conjugate of claim 1.
